

AHA SCIENTIFIC STATEMENT

Obesity and Cardiovascular Disease

A Scientific Statement From the American Heart Association

ABSTRACT: The global obesity epidemic is well established, with increases in obesity prevalence for most countries since the 1980s. Obesity contributes directly to incident cardiovascular risk factors, including dyslipidemia, type 2 diabetes, hypertension, and sleep disorders. Obesity also leads to the development of cardiovascular disease and cardiovascular disease mortality independently of other cardiovascular risk factors. More recent data highlight abdominal obesity, as determined by waist circumference, as a cardiovascular disease risk marker that is independent of body mass index. There have also been significant advances in imaging modalities for characterizing body composition, including visceral adiposity. Studies that quantify fat depots, including ectopic fat, support excess visceral adiposity as an independent indicator of poor cardiovascular outcomes. Lifestyle modification and subsequent weight loss improve both metabolic syndrome and associated systemic inflammation and endothelial dysfunction. However, clinical trials of medical weight loss have not demonstrated a reduction in coronary artery disease rates. In contrast, prospective studies comparing patients undergoing bariatric surgery with nonsurgical patients with obesity have shown reduced coronary artery disease risk with surgery. In this statement, we summarize the impact of obesity on the diagnosis, clinical management, and outcomes of atherosclerotic cardiovascular disease, heart failure, and arrhythmias, especially sudden cardiac death and atrial fibrillation. In particular, we examine the influence of obesity on noninvasive and invasive diagnostic procedures for coronary artery disease. Moreover, we review the impact of obesity on cardiac function and outcomes related to heart failure with reduced and preserved ejection fraction. Finally, we describe the effects of lifestyle and surgical weight loss interventions on outcomes related to coronary artery disease, heart failure, and atrial fibrillation.

Tiffany M. Powell-Wiley, MD, MPH, FAHA, Chair
Paul Poirier, MD, PhD, FAHA, Vice Chair
Lora E. Burke, PhD, MPH, FAHA
Jean-Pierre Després, PhD, FAHA
Penny Gordon-Larsen, PhD, FAHA
Carl J. Lavie, MD
Scott A. Lear, PhD, FAHA
Chiadi E. Ndumele, MD, PhD, FAHA
Ian J. Neeland, MD, FAHA
Prashanthan Sanders, MBBS (Hons), PhD, FAHA
Marie-Pierre St-Onge, PhD, FAHA
On behalf of the American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council

Key Words: AHA Scientific Statements
■ atrial fibrillation ■ cardiovascular diseases ■ coronary artery disease
■ death, sudden ■ heart ■ heart failure
■ obesity

© 2021 American Heart Association, Inc.

<https://www.ahajournals.org/journal/circ>

Obesity is a multifactorial disease with a complex pathogenesis related to biological,¹ psychosocial,² socioeconomic,³ and environmental^{4,5} factors and heterogeneity in the pathways and mechanisms by which it leads to adverse health outcomes.^{6–8} The “2013 AHA [American Heart Association]/ACC [American College of Cardiology]/TOS [The Obesity Society] Guideline for the Management of Overweight and Obesity in Adults”⁷ uses the World Health Organization criteria⁹ to define overweight as a body mass index (BMI) ≥ 25 and < 30 kg/m² and obesity as a BMI ≥ 30 kg/m².⁷ Although BMI is strongly correlated with percent body fat across populations, there are limitations in its predictive ability to estimate body fat for any given individual,^{10–12} with considerable variation by sex, age, and race/ethnicity.^{13,14} Country-specific cut points have been developed for Asian subpopulations such as in China, for which cut points of 24 kg/m² for overweight and 28 kg/m² for obesity are recommended.¹⁵ The GBD (Global Burden of Disease) Obesity Collaborators estimated that a total of 603.7 million adults had obesity, with obesity prevalence doubling between 1980 and 2015 in 73 countries and continuously increasing in most of the other countries.¹⁶ It is estimated that 39% to 49% of the world’s population (2.8–3.5 billion people) have overweight or obesity.¹⁷ In addition, the GBD investigators found an increase in the burden of elevated BMI, with high BMI accounting for 4.0 million deaths in 2015, more than two-thirds of which were caused by cardiovascular disease (CVD),¹⁶ even after accounting for smoking and ill health.¹⁸ Furthermore, a large proportion of both BMI-related deaths (41%) and BMI-related disability-adjusted life-years (34%) were caused by CVD among individuals with obesity.¹⁶ The most recent nationally representative US estimates for obesity prevalence based on the National Health and Nutrition Examination Survey reported a crude prevalence of 39.8% in 2015 to 2016, which is an increase from the crude prevalence of 37.9% in 2013 to 2014.¹⁹ The prevalence of class 3 obesity (BMI ≥ 40 kg/m²) is relatively high at an unadjusted prevalence of 7.7% in the total sample, with racial/ethnic and sex differences in class 3 obesity prevalence ranging from 5.5% in non-Hispanic White men to 16.9% in non-Hispanic Black women.¹⁹ Important contributors to racial/ethnic differences in obesity prevalence in the United States include racial/ethnic discrimination,^{20,21} weight stigmatization,²² and disproportionate experience of psychosocial stressors,²³ as well as structural racism that promotes obesogenic environments and socioeconomic inequalities.²⁴ Disparate exposure to psychosocial and environmental factors that contribute to both obesity and other CVD risk factors directly relates to disparities in CVD outcomes across racial/ethnic groups in the United States.²⁵ Among pediatric populations, adolescent obesity is a global health epidemic; worldwide, marked increases

in obesity prevalence among adolescents over the past 35 years ultimately contribute to CVD risk into adulthood.²⁶ Moreover, the trends in obesity prevalence in the United States and around the world highlight the significant impact that obesity will continue to have on CVD incidence and prevalence globally. Therefore, the purpose of this scientific statement is to provide an update to the 2006 American Heart Association scientific statement “Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss.”²⁷ Although obesity is linked to numerous diseases of the cardiovascular system, including stroke, venous thromboembolic disease, and pulmonary hypertension,^{28,29} this statement focuses on the impact of obesity on the pathophysiology, diagnosis, treatment, and clinical outcomes of atherosclerotic CVD, heart failure (HF), and arrhythmias, especially sudden cardiac death (SCD) and atrial fibrillation (AF). Before focusing on the relationship between obesity and these CVD outcomes, we review recent data linking abdominal obesity and visceral adiposity to CVD risk.

VISCERAL ADIPOSITY, LIVER FAT, AND CVD RISK



There is a strong correlation between overall obesity and abdominal obesity; however, some individuals may be classified as having overall obesity but not abdominal obesity. The converse may occur as well with abdominal obesity in the absence of overall obesity based on the BMI definition of obesity. The presence of cardiometabolic disease and CVD in those with “normal-weight obesity” leads to misclassification and underdiagnosis of CVD risk in clinical practice, particularly among patients who have excess fat but not obesity as classified by BMI.^{30–32} Thus, high waist circumference (WC) even in individuals with normal weight may unmask higher CVD risk because WC is an indicator of abdominal body fat, which is associated with cardiometabolic disease and CVD and is predictive of mortality.^{33,34} WC as a measure of abdominal obesity provides an indicator of body composition and adds critical information along with BMI.³³ Several organizations and expert panels have recommended that WC measures be assessed along with BMI in clinical evaluations^{7,14,35,36} because increasing evidence supports visceral adiposity as a marker of cardiovascular risk.^{37–39}

The development of imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) has been a remarkable advance in the study of human body composition and of its relationship with CVD risk.^{40,41} With these methods, cross-sectional images of the body at any level allow the quantification of areas or volumes of various adipose tissue and ectopic fat depots. An ectopic fat depot is

generally considered a lipid deposit that is not physiologically stored in adipose tissues such as in the liver, the pancreas, the heart, and skeletal muscle.⁴² Cohort imaging studies have shown that all adipose and ectopic fat depots are correlated with one another.^{43,44} However, at any BMI or total adiposity level, there is considerable individual variation in the amount of subcutaneous versus intra-abdominal or visceral adipose tissue (VAT) in the abdominal cavity.^{42,45,46} There may be a 2- to 3-fold variation in the amount of VAT at any level of total or subcutaneous adiposity.^{42,43,47} Within overweight and obese categories, individuals with low levels of VAT are characterized by a more favorable CVD risk profile, sometimes referred to as metabolically healthy obesity.^{48,49} Recent data suggest that metabolically healthy obesity may be a transient phenotype for the majority of the population, with the duration of metabolically healthy obesity differing by race/ethnicity and sex.⁴⁹ When those with metabolically healthy obesity are compared with patients with excess VAT, those with excess VAT represent a subgroup of individuals at highest CVD risk, regardless of BMI.^{42,46,50} Studies that have examined the relationships between VAT and cardiovascular outcomes have also confirmed that VAT serves as a clear health hazard.^{51–53} Imaging studies have shown that a frequent partner of visceral obesity is higher liver fat accumulation,^{54,55} for which nonalcoholic fatty liver disease is a clinical manifestation.⁵⁶ Overall, excess liver fat has generally been associated with the same alterations in cardiovascular risk factors as visceral obesity.^{56,57} However, the question remains as to whether excess liver fat in isolation is associated with higher cardiovascular risk. Mendelian randomization studies that have measured genetic variants predisposing to higher liver fat have not been able to show associations with CVD.⁵⁸ Excess liver fat is likely to play a major role in the pathogenesis of the dysmetabolic state that can be found in individuals with overweight/obesity.⁵⁹ From a clinical standpoint, health care practitioners should be aware of the fact that the most prevalent form of non-alcoholic fatty liver disease is found among individuals with excess VAT.^{60,61} Thus, from a prevention standpoint, reducing visceral obesity by promoting improved lifestyle habits is key to addressing the current epidemic of nonalcoholic fatty liver disease.

ECTOPIC FAT DEPOTS AND CVD RISK

Other ectopic fat depots of interest are pericardial and epicardial adipose tissues. In the literature, the two are often used interchangeably but have distinct anatomic locations and functions that should be clearly defined.⁶² Pericardial fat can be imaged with CT and consists of the total fat content within the pericardial sac⁶³ below the superior extent of the left^{64,65} or right⁶⁶ main

coronary artery. This depot has been associated with higher BMI, traditional cardiovascular risk factors, and more atherogenic lipoprotein particles.⁶⁴ Pericardial fat correlates with CVD after adjustment for age, sex, BMI, and WC but not after adjustment for cardiovascular risk factors.⁶³ In the Multi-Ethnic Study of Atherosclerosis, pericardial fat was associated with a higher risk of all-cause CVD, hard atherosclerotic CVD, and HF.⁶⁵ Adding pericardial fat to clinical parameters and coronary artery calcium (CAC) scores improved risk discrimination for these outcomes. In the Rancho Bernardo Study, all-cause mortality risk was higher by 34% per 1-SD increment in pericardial fat after adjustment for age, sex, lifestyle variables, lipids, glucose, and adipocytokines.⁶⁶ However, this study did not show that pericardial fat was predictive of incident CVD beyond traditional risk factors; additional studies must be done to assess this relationship. Epicardial adipose tissue represents visceral fat between the outer wall of the myocardium and the visceral layer of the pericardium. This adipose tissue originates from embryonic brown adipose tissue and releases cytokines and chemokines into the vasculature.⁶⁷ It has been associated with overall cardiovascular health score⁶⁸ and arterial stiffness in patients with CVD and type 2 diabetes.⁶⁹ Studies have shown that epicardial adipose tissue thickness is significantly correlated with WC, blood pressure, markers of insulin resistance, and dyslipidemia,^{68,70} suggesting that this adipose tissue depot could be considered highly insulin resistant and may be an indicator of cardiovascular risk. In addition, epicardial fat thickness has been shown to be associated with sleep apnea severity in women independently of BMI,⁷¹ and sleep apnea is associated with higher CVD risk.⁷² This fat depot can be mobilized, with reductions observed after continuous positive airway pressure treatment.⁷¹ However, short-term (8–12 weeks) continuous positive airway pressure use in patients with sleep apnea does not appear to affect VAT.^{73,74} One must question, then, whether thicker epicardial fat is a predictor or a consequence of sleep-disordered breathing.

IMPACT OF LIFESTYLE INTERVENTIONS ON ECTOPIC/PERICARDIAL FAT

Given the associations of ectopic fat with CVD risk, numerous interventions to reduce these adipose tissue depots have been investigated. Although a number of pharmacological agents exist to reduce body fat, lifestyle interventions such as the Diabetes Prevention Program may be as effective as, if not more effective than, medications.^{75,76} Randomized studies in both men and women across varying ages have found that exercise, usually 3 to 5 sessions per week for 12 to 52 weeks, reduces VAT compared with a nonexercise control group.^{77–79} Well-controlled studies have demonstrated

that exercise can reduce VAT even in the absence of weight loss,⁷⁷⁻⁷⁹ and a meta-analysis reported exercise to result in a 6.1% loss of VAT in the absence of weight loss.⁸⁰ Loss of VAT in the absence of weight loss may relate to increases in fat-free mass.⁸¹ However, not all studies have demonstrated a significant reduction of VAT compared with control.^{82,83} The most beneficial exercise interventions appear to be aerobic in nature; data on the reductions of VAT by only resistance training are equivocal.^{84,85} Similarly, reductions in VAT with high-intensity exercise have not been consistently superior to those with moderate-intensity exercise,^{86,87} and even 3 months of walking resulted in greater VAT reductions compared with control.⁸⁸ Meeting the current recommendations for physical activity of 150 min/wk may be sufficient to reduce VAT, with no further reductions with additional activity.⁸⁹ Interventions targeting weight loss through caloric restriction have also demonstrated effectiveness in reducing VAT.^{90,91} Compared with dietary interventions, exercise interventions have demonstrated greater VAT reductions in most studies^{92,93} and in a meta-analysis⁸⁰ but not in all studies.^{90,91,94} Combined interventions carried out in the Diabetes Prevention Program and the Look AHEAD Trial (Action for Health in Diabetes) have reported greater VAT reductions compared with control groups.^{75,95} Exercise interventions also appear to be effective at reducing hepatic^{96,97} and epicardial and pericardial fat.^{98,99} However, a meta-analysis did not find a significant reduction in epicardial fat with exercise.¹⁰⁰ Caloric restriction has been demonstrated to reduce hepatic¹⁰¹ and epicardial and pericardial fat.^{100,102}

OTHER ADIPOSITY AND BODY COMPOSITION MEASURES

Although WC is meaningful on its own, the ratio of WC to height, which takes body size into account, may be a better predictor of CVD and may be considered a measure of adiposity.^{103,104} Moreover, waist-to-hip ratio (WHR) has been shown to predict cardiovascular mortality independently of BMI. According to data from the National Health and Nutrition Examination Survey, those in the US population with a WHR indicative of central obesity had a higher risk of cardiovascular mortality compared with those with the same BMI but without central adiposity.^{34,105} Nonanthropometric measures based on CT, MRI, ultrasonography, dual-energy x-ray absorptiometry, air displacement plethysmography, and bioelectric impedance analysis can be used to quantify body composition. Details on how these body composition measures relate to cardiovascular risk have been summarized in the American Heart Association scientific statement "Identification of Obesity and Cardiovascular Risk in Ethnically and Racially Diverse Populations."¹⁴

Thus, visceral adiposity as measured by WC, WHR, or detailed imaging methods has been shown to be a risk factor for CVD independently of BMI. Lifestyle interventions, particularly physical activity interventions or interventions combining dietary changes and physical activity, have been shown to reduce VAT and ectopic fat, in some cases independently of weight loss.

PATHOPHYSIOLOGY OF CORONARY ARTERY DISEASE IN OBESITY

Atherosclerosis and Coronary Artery Disease

The atherosclerotic process is initiated in childhood, with ingestion of cholesterol esters by macrophage foam cells and their deposition in vessel walls resulting in thickening of the arterial intima. Further lipid accumulation leads to the development of fatty streaks,¹⁰⁶ which appear to be nearly ubiquitously present in young adults.¹⁰⁷ Obesity accelerates these early atherosclerotic changes through several mechanisms, including insulin resistance and inflammation.¹⁰⁸ Obesity and several related downstream metabolic cardiovascular risk factors, including elevated blood pressure, dyslipidemia, and hyperglycemia, have been linked to the extent of atherosclerotic disease in autopsy studies of children and young adults.^{109,110} However, obesity is associated with overt atherosclerotic lesions even after accounting for the impact of these metabolic cardiovascular risk factors. The association of obesity with raised atherosclerotic lesions among men in the Pathobiological Determinants of Atherosclerosis in Youth study was present only for those with a thick abdominal panniculus, indicating the fundamental role of central adiposity in the development of atherosclerotic disease.¹¹¹ Visceral adiposity promotes systemic and vascular inflammation, which is fundamental to all aspects of the atherosclerotic process, from fatty streak development to atherothrombosis.^{112,113} Inflammation induced by obesity increases the likelihood of low-density lipoprotein oxidation,¹¹⁴ which in turn promotes atherogenesis. Insulin resistance is associated with dyslipidemia (high triglycerides; low high-density lipoprotein cholesterol; small, dense low-density lipoprotein particles) and metabolic syndrome (multiplex CVD risk factor including abdominal obesity, atherogenic dyslipidemia, elevated blood pressure, insulin resistance with or without glucose intolerance, and proinflammatory and prothrombotic states), which are linked to atherosclerosis.¹¹⁵ Endothelial dysfunction in obesity, principally caused by diminished bioavailability of nitric oxide in the setting of inflammation and oxidative stress,¹¹⁶ is also fundamental to atherosclerosis progression. Carotid intima-media thickness as an early marker of atherosclerosis in young

adults is associated with obesity,¹¹⁷ particularly chronically elevated weight from youth through adulthood.¹¹⁸

Incident Coronary Artery Disease Events

Several prospective epidemiological studies demonstrate that obesity is associated with higher risk of incident coronary artery disease (CAD).^{119–122} A meta-analysis of >300 000 adults with 18 000 CAD events demonstrated that BMI in the overweight and obese ranges was associated with elevated CAD risk.¹²³ Of clinical importance, at each level of BMI, higher measures of central adiposity, including WC and WHR, were associated with a greater risk of CAD and cardiovascular mortality, including among those with normal weight as assessed by BMI.^{31,34,105,124,125} The degree and duration of obesity, as measured by total cumulative exposure to excess overall and abdominal adiposity and expressed as excess BMI-years and WC-years, have been shown to be stronger predictors of CAD events beyond BMI or WC alone.¹²⁶ There are conflicting results on the extent to which the association of obesity with CAD is independent of the metabolic cardiovascular risk factors linked to excess weight. Some large prospective analyses have indicated that the link between obesity and CAD is mediated largely by hypertension, dyslipidemia, diabetes, and other comorbidities,¹²⁷ whereas other prospective studies suggest a significant residual CAD risk in obesity even after accounting for these risk factors.^{120,128} Similarly, some studies have indicated that obesity without metabolic syndrome is not associated with incident myocardial infarction,¹²⁹ in contrast to other studies.^{130,131} A meta-analysis of 21 studies including 1.8 million individuals suggested that approximately half of the associations of overweight and obesity with CAD are explained by levels of blood pressure, cholesterol, and glucose.¹³² However, this may be an underestimation resulting from residual confounding from cardiovascular risk factors assessed at a single time point or not measured directly in some studies. Production of adipocytokines, oxidative stress, and a prothrombotic state in individuals with metabolic syndrome may contribute to CAD risk beyond that explained by routinely measured cardiovascular risk factors.¹¹⁵ Ectopic fat deposition, including within the pericardial and epicardial spaces, may further contribute to the burden of coronary atherosclerosis.¹³³ A pathological study in humans reported that part of the left anterior descending artery with an intramyocardial course was in perfect condition (ie, without any intimal atherosclerotic lesion), which was in contrast to the epicardial segment of the same artery in which atherosclerosis was documented.¹³⁴ Likewise, in hypercholesterolemic rabbits, epicardial coronary arteries surrounded by adipose tissue develop atherosclerosis, whereas the intramyocardial segments of the same arteries remain unaltered.¹³⁵ Thus, local

production of adipocytokines by epicardial fat may modulate blood vessel biology through paracrine signaling or through vasa vasorum.

Obesity and Microvascular Disease

In addition to the effects of excess adiposity on epicardial coronary vessels described above, obesity is linked to abnormalities in the coronary microvasculature, a key regulator of coronary blood flow.^{136,137} Coronary microvascular disease often coexists with and compounds the effects of obstructive or nonobstructive CAD on myocardial ischemia and CAD events.^{138,139} Coronary microvascular disease is pathophysiologically linked to endothelial dysfunction and possibly to small vessel remodeling; this microvascular disease is independently associated with higher BMI¹⁴⁰ and provides independent prognostic information on cardiovascular risk among those with obesity.¹⁴¹ In prospective studies, weight loss via bariatric surgery has been associated with improvements in coronary microvascular function.¹⁴²

DIAGNOSIS OF CAD IN OBESITY

CAD assessment can be challenging in patients with obesity. The baseline ECG may be influenced by obesity, and patients with obesity have impaired maximal exercise testing capacity (dyspnea, mechanical limitations, left ventricular [LV] diastolic dysfunction [LVDD]).²⁷ Thus, other modalities such as nuclear medicine approaches, stress echocardiography, or pharmacological stress and stress cardiac MRI may be of interest in the evaluation of CAD in this population. CAC screening and CT coronary angiography can be used in diagnosing CAD, but ultimately, coronary angiography remains the gold standard test for identifying the presence and extent of CAD. Here, we review specific considerations for the use of noninvasive and invasive modalities to assess CAD in patients with obesity (summarized in Table 1).

Noninvasive CAD Assessment in Obesity

Electrocardiographic Assessment

Obesity has the potential to affect the ECG in several ways: displacing the heart by elevating the diaphragm in the supine position, increasing the cardiac workload, and increasing the distance between the heart and the recording electrodes.²⁷ Several electrocardiographic changes are associated with obesity (Table 2). More frequent ST-segment depression is seen in patients with overweight and CAD,¹⁴³ and insulin concentration may be related to the development of the ST-segment depression over time.¹⁴⁴ Multiple electrocardiographic criteria for LV hypertrophy (LVH) are present more regularly in patients with severe obesity compared with individuals with normal weight but less frequently than

Table 1. Considerations for Use of Noninvasive and Invasive Diagnostic Tools in Patients With Obesity

| Diagnostic tool | Strengths | Limitations |
|---------------------------------|---|--|
| Noninvasive diagnostic tools | | |
| ECG | Widely available, cheap | Low sensitivity and specificity |
| Treadmill stress test | Widely available Functional testing | Patients may stop because of symptoms unrelated to CVD |
| SPECT | Available, good precision | Irradiation, technical limitation because of body size Residual uncorrected attenuation |
| PET (rubidium) | Nuclear imaging technique of choice for patients with obesity | Less radiation exposure than SPECT but technical limitations because of body size |
| Stress echocardiography | Widely available, valid technique in patients with obesity Radiation free Has no weight limits Functional testing | Highly operator dependent Can be limited because of poor acoustic windows related to pulmonary disease, breast size, obesity, and respiratory motion |
| Stress cardiac MRI | Accurate assessment of the complex cardiac effect of chronic pressure overload and high cardiac output in patients with obesity | Table weight limit WC may limit access depending on bore diameter Length of examination Claustrophobia |
| CT calcium scan | Inexpensive and reproducible technique to determine the presence and extent of CAC | Obesity may limit the diagnostic accuracy and value of cardiac CT calcium scan Gantry/bore diameter limitations |
| Invasive diagnostic tools | | |
| Cardiac CT coronary angiography | Sensitivity and negative predictive values are high in patients with obesity | Image quality degrades as BMI increases Degradation is related to an increase in background noise, subsequent reduced signal-to-noise ratio, and low vessel opacification |
| Intravascular ultrasound | Allows in vivo assessment of plaque burden, plaque morphology (ie, stages of plaque development, high-risk plaque features) | Invasive technique |

BMI indicates body mass index; CAC, coronary artery calcium; CT, computed tomography; CVD, cardiovascular disease; MRI, magnetic resonance imaging; PET, positron emission tomography; SPECT, single photon emission computed tomography; and WC, waist circumference.

would be expected on the basis of the high prevalence of echocardiographic criteria for LVH.²⁷ Therefore, LVH is probably underdiagnosed according to the usual ECG criteria in individuals with severe obesity. In LVH and in obesity, the heart is oriented more horizontally in the mediastinum, which may explain the usefulness of the R wave in AVL.²⁷ Thus, it has been proposed that for men of all ages, LVH is considered present on the basis of the QRS voltage alone when the amplitudes of the R wave in lead AVL and the S wave in lead V₃ are >35 mm. For women, the same criteria were set at >25 mm.²⁷ When electrocardiographic voltage criteria were compared with LV mass estimated by echocardiography, a sensitivity of 49%, specificity of 93%, and overall accuracy of 76% were reported.²⁷ These percentages representing the Cornell score are higher than other widely used criteria such as the Sokolow-Lyon voltage or Romhilt-Estes score.

Treadmill Stress Test

Standard treadmill stress test performance is limited in patients with obesity by several factors. Electrocardiographic abnormalities seen with obesity might limit accurate interpretation, and aerobic capacity can be

diminished because of pulmonary dysfunction, orthopedic limitations, and LVDD.¹⁴⁵ Many patients with obesity fail to achieve 80% to 85% of the age-predicted heart rate needed for diagnostically valid results.^{146,147} Chronotropic competence can be reduced in obesity, with a prior study showing that peak heart rate, heart rate recovery, and chronotropic index are lower in patients with obesity, regardless of fitness level.¹⁴⁶ Higher systolic and diastolic blood pressures also may be observed during the exercise stress test in patients with obesity.¹⁴⁸ However, standard Bruce and modified Ramp protocols achieve valid results in most patients with obesity, with patients terminating the test because of fatigue, leg pain, or dyspnea.¹⁴⁹

Single Photon Emission CT

Single photon emission CT can be used with exercise, vasodilator (dipyridamole), and dobutamine stress. Two-day protocols with larger tracer doses, which are weight based, are recommended in patients who weigh 250 to 350 lb (113–160 kg). Attenuation artifacts, most commonly resulting from attenuation by the diaphragm or breast, are common in obesity. Tissue attenuation

Table 2. Electrocardiographic Changes That May Occur in Individuals With Obesity

| |
|--|
| Clinically significant |
| ↑ Heart rate |
| ↑ QRS interval |
| ↑ QTc interval |
| False-positive criteria for inferior myocardial infarction |
| Less clinically significant |
| ↑ PR interval |
| ↑ QRS voltage |
| ↑ QT dispersion |
| ↑ SAECG (late potentials) |
| ↑ ST-T abnormalities |
| ↑ ST-segment depression |
| Left axis deviation |
| Flattening of the T wave (inferolateral leads) |
| Left atrial abnormalities |

SAECG indicates signal-averaged ECG.

Adapted from Poirier et al.²⁷ Copyright © 2006, American Heart Association, Inc.

decreases single photon emission CT image quality and thus diagnostic accuracy. Improved cameras, software, and CT-based attenuation correction algorithms are techniques that enable a reduction of attenuation artifacts. Technetium sestamibi is the marker of choice in patients with obesity because of greater energy emission, which generates better images.¹⁵⁰ Disadvantages include the limitations of relative perfusion imaging with reduced ability to detect triple-vessel or left main stem disease and residual uncorrected attenuation. Weight-based limitations might occur at 350 lb (160 kg), which might necessitate planar imaging. Newer and more sensitive cameras might eliminate some of these issues, but their use still leads to table weight and size issues because proper positioning of the patient is required with this system. Thus, single photon emission CT is generally avoided when the patient's BMI is >35 kg/m² because of the above limitations, and positron emission tomography (PET) is recommended in those cases when looking for myocardial ischemia and an imaging modality is indicated.

PET Rubidium

PET rubidium has a 91% sensitivity and 89% specificity; is faster than sestamibi single photon emission CT; and produces less radiation exposure, better-quality images, correction for attenuation, a greater degree of diagnostic precision, and a reduced need for invasive examinations. Normal PET myocardial perfusion imaging is associated with very low cardiac death rates in all categories of obesity.¹⁵¹ PET allows the ability to quantify absolute coronary blood flow, adding to the diagnostic and prognostic capabilities beyond relative

perfusion imaging, especially in the detection of triple-vessel and left main stem disease. Therefore, PET rubidium is the nuclear imaging technique of choice for patients with obesity.

Stress Echocardiography

Despite some limitations, exercise stress echocardiography is a valid technique in patients with obesity.^{152,153} Stress echocardiography is highly feasible in most cases for patients with obesity through either physiological stress (treadmill exercise) or pharmacological stress (dobutamine). It is widely available, low cost, and radiation free and has no weight limits. However, stress echocardiography is highly operator dependent and can be limited in the presence of poor acoustic windows related to pulmonary disease, breast size, obesity, and respiratory motion.¹⁵⁴ Excellent 1-year outcomes have been shown in patients with obesity and normal stress echocardiography.¹⁵⁵ Contrast injection can be used to improve the number of heart segments visualized.¹⁵⁵ In a prospective study of patients with overweight and obesity who underwent coronary angiography and dobutamine stress echocardiography with and without contrast, contrasted images improved sensitivity and specificity (82% versus 70% and 78% versus 67% with and without contrast, respectively).¹⁵⁴ Retrospectively, Lerakis et al¹⁵⁶ assessed dobutamine stress echocardiography as a preoperative screen for CAD in a bariatric surgery population. Adequate imaging was obtained in 97% of patients in light of intravenous echocardiographic contrast use in 72% of cases. Indeed, higher rates of contrast use have been reported in patients with severe obesity who undergo transthoracic dobutamine echocardiography.^{152,153,157,158} If severe limitations exist, transesophageal echocardiography with dobutamine might be useful.^{159,160}

Stress Cardiac MRI

Stress cardiac MRI is a technique that allows the assessment of perfusion defects, regional wall motion abnormalities, and LV ejection fraction and the detection of scar with the use of gadolinium. It allows accurate assessment of the complex cardiac effect of chronic pressure overload and high cardiac output in patients with obesity.^{153,155} Stress cardiac MRI and PET are likely the diagnostic techniques least affected by obesity. Newer-generation MRIs have larger bore sizes (70 instead of 60 cm) and greater magnet strengths, which have accommodated patients with obesity more easily and led to improved image quality. The usefulness of stress cardiac MRI was studied in 285 participants with an average BMI of 34 kg/m² who underwent testing and long-term follow-up. Of the patients imaged, 89% had diagnostic image quality.¹⁶¹ The presence of ischemia predicted adverse events at 5 years of follow-up, regardless of whether scar was present. Lack of inducible ischemia is associated with a low annual major adverse coronary

events (MACEs) rate of 0.3% at 2 years in patients with obesity.¹⁶¹ Table weight limit, bore diameter, and length can be significant limitations, and some centers might not be able to accommodate patients with more severe obesity despite the benefits of diagnosis. Besides the weight limit of 335 lb (152 kg) that comes with MRI tables, higher WC and claustrophobia might also limit the feasibility of MRI in patients with severe obesity.¹⁵⁵

CT Calcium Scan

Obesity is associated with elevated CAC, a marker of coronary atherosclerosis that is predictive of cardiovascular events^{162,163} and more rapid CAC progression.¹⁶⁴ The presence of high CAC score offers an inexpensive and reproducible technique to determine the presence and extent of calcified coronary artery plaque. Despite advances in CT scanners, obesity may limit the diagnostic accuracy and value of cardiac CT calcium scan. CT equipment has table weight limits of 350 to 450 lb (160–204 kg) and is also limited by gantry/bore diameter. Studies suggest that WC and WHR provide more useful prognostic information than BMI on the likelihood of elevated CAC,^{165,166} again indicating the importance of abdominal obesity in the pathophysiology of atherosclerosis.

Cardiac CT Coronary Angiography

CT coronary angiography is emerging as an alternative approach for the quantification of both coronary calcified and noncalcified plaque. This approach may be particularly useful in specific subsets of symptomatic patients with obesity, unknown CVD, and equivocal or uninterpretable stress tests or in cases when a discrepancy exists between clinical presentation and stress test results. CAC score allows risk stratification and plaque burden assessment, whereas CT coronary angiography allows evaluation of luminal stenosis and plaque characterization and quantification. Registry data showed that those with obesity who were symptomatic were more likely than patients without obesity to have any CVD at CT coronary angiography.¹⁶⁷ Imai et al¹⁶⁸ studied 553 patients who underwent serial CT coronary angiography and observed that the risk of noncalcified plaques became higher as abdominal visceral adiposity was higher, with the highest quartile conferring the greatest risk, regardless of underlying cardiovascular risk factors. One major challenge with CT coronary angiography is that image quality degrades as BMI increases; this degradation is related to an increase in background noise and subsequent reduced signal-to-noise ratio. In addition, low vessel opacification may occur in patients with overweight or obesity because of differences in the distribution of blood volume in peripheral venous and central circulation when contrast is injected,¹⁶⁹ which ultimately leads to a higher rate of nonevaluable segments in patients with overweight or

obesity. Nevertheless, sensitivity and negative predictive values are invariably high even in patients with obesity.

Invasive Evaluation of CAD in Obesity

Coronary Angiography

Individuals with obesity have several limitations when undergoing evaluation in the catheterization laboratory. Potential technical difficulties include suboptimal radiographic visualization that may limit detection of angiographic results and may result in a greater likelihood of complications. Vascular access may be laborious; radial access is preferred in this population because of fewer vascular complications, especially bleeding, earlier ambulation, and a shorter hospital stay.^{170,171} When cardiac catheterization is pursued for diagnostic or therapeutic purposes for those with severe obesity, radial artery access has been associated with a 3 times lower rate of complications than a transfemoral approach.¹⁷⁰ The radial approach is particularly useful for patients with limited capability to tolerate supine positions because upright mobilization can be immediate after the procedure. If the femoral approach is used, vascular closure devices should be used to accelerate ambulation in patients with obesity.¹⁷² The fluoroscopy needed to achieve adequate x-ray penetration and sufficient image quality may also result in higher radiation exposure to both patients with obesity and staff.¹⁷³ In addition to issues with vascular access and radiographic imaging, the engineering parameters and physical limitations of the catheterization table and its supporting structures may limit patients' ability to undergo clinically indicated coronary angiography.

Intravascular Ultrasound

Several intravascular imaging techniques such as intravascular ultrasound, virtual histology intravascular ultrasound, and optical coherence tomography allow in vivo assessment of plaque burden, plaque morphology (ie, stages of plaque development, high-risk plaque features), and response to therapy, particularly for higher-risk patients. In a large retrospective database of 3158 patients designed to evaluate plaque characteristics, 32% of patients with BMI >25 kg/m² demonstrated evidence of high-risk plaque features (positive remodeling, spotty calcification, and low-attenuation plaque), and BMI itself was an independent predictor of future acute coronary syndrome events.¹⁷⁴ Abdominal visceral adiposity independently predicted the presence and extent of noncalcified coronary plaque that also contained multiple features of plaque vulnerability.¹⁷⁵ Thus, numerous tests can diagnose atherosclerosis, myocardial ischemia, or both. The appropriate choice of test to assess CVD depends on local expertise, the relative strengths and weaknesses of each modality, and individual patient characteristics that contribute to the

pretest likelihood of CVD and the risk/benefit ratio of using a given modality.

CLINICAL MANAGEMENT AND TREATMENT OF CAD IN OBESITY

The Obesity Paradox

Obesity is a strong risk factor for the development of CVD because patients with obesity experience CVD events at an earlier age, live with CVD for a greater proportion of their lifetime, and have a shorter average life span than individuals with normal weight.¹⁷⁶ However, in patients with overweight or obesity, particularly among those who develop symptomatic CVD, BMI and other parameters of body composition are not consistent cardiovascular risk factors for adverse short-term CVD outcomes (≤ 10 years).^{177–179} This reversal of traditional epidemiology, called the obesity paradox, is now well documented in numerous studies, particularly in diverse populations who have overweight or class 1 obesity. The underlying cause of the obesity paradox is unclear. The paradox may relate to potential lead time bias that occurs when patients with overweight or obesity develop CVD earlier in their lifetime or are tested earlier for CVD than patients with normal weight, resulting in earlier diagnoses and treatment and confounding differences in outcomes. In addition, differences in cardiorespiratory fitness may explain more favorable CVD outcomes regardless of BMI. Finally, some propose that a “lean paradox” may exist in which low body fat percentage and low BMI with less reserve to avoid cardiac cachexia may be the more pertinent predictors of poor CVD outcomes.^{177–179}

Weight Loss and CAD Risk

Lifestyle modification, with associated weight loss, improves both the diagnostic components of metabolic syndrome and associated pathophysiologic abnormalities such as systemic inflammation and endothelial dysfunction.^{27,180,181} Interventional trials of medical weight loss have not demonstrated a clear reduction in CAD rates.^{182–184} In contrast, reduced CAD risk has been demonstrated in prospective studies comparing patients undergoing bariatric surgery with nonsurgical patients with obesity, with the Swedish Obesity Study finding significantly lower rates of fatal and nonfatal cardiovascular events in those undergoing bariatric surgery.¹⁸⁵ The reason for the disparate results of medical and surgical weight loss studies is likely the degree of weight loss achieved (5–10 kg with medical weight loss versus 10–40 kg with surgery) and the risk factor reduction seen with bariatric surgery.¹⁸⁶ Modest short-term weight loss may not be sufficient to fully overcome the deleterious effects of long-term obesity on the vasculature.

Benefits of Weight Loss on CAD

The general goals of weight loss and management are, at a minimum, to prevent further weight gain, to reduce body weight, and to maintain a lower body weight over the long term. Patients should have their BMI and WC measured not only for the initial assessment of the degree of overweight and obesity but also as a guide to the efficacy of weight loss treatment.¹⁸⁷ The Mediterranean diet decreases MACEs in patients with high cardiovascular risk and is an interesting option for this population.¹⁸⁸ Future studies should determine how much adherence to a Mediterranean dietary pattern is needed or how best to personalize diets on the basis of genetic or other objective factors for CVD risk reduction in obesity.¹⁸⁹ Moreover, no studies have shown a clear reduction of CVD or mortality with weight loss through lifestyle modification. Look AHEAD, one of the largest clinical trials of lifestyle modification for obesity treatment in patients with type 2 diabetes, failed to show a significant reduction of MACEs or cardiovascular mortality after 9.6 years, which may be related to the limited differential weight loss between the intervention and control groups by the end of the trial.¹⁸² Post hoc analyses of Look AHEAD showed that participants who lost $\geq 10\%$ of their body weight had significant reductions in cardiovascular events.¹⁹⁰ In addition, physical activity, particularly aerobic exercise, is associated with improved insulin sensitivity, endothelial function, and reduction in proinflammatory markers independently of weight loss,¹⁸⁹ but more data are needed in populations with CVD. Liraglutide has been shown to reduce MACEs and cardiovascular death in the LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results), but this was in a population with type 2 diabetes who were using the 1.8-mg dosing specified for diabetes treatment.¹⁹¹ Lorcaserin appeared to be safe in terms of CVD, but no benefits in cardiovascular mortality or CVD events were demonstrated (Lorcaserin was removed from the US market by the US Food and Drug Administration in 2020).¹⁹² An interim analysis of the LIGHT trial (Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors) showed that naltrexone-bupropion has cardiovascular safety; however, no solid conclusion can be drawn from this trial given that it was terminated early because of public release of the interim data by the sponsor.¹⁹³ A retrospective study of 20235 surgical and nonsurgical patients¹⁹⁴ showed that bariatric surgery is associated with a lower incidence of macrovascular disease (first occurrence of CAD or cerebrovascular events) driven mainly by a lower incidence of CAD (acute myocardial infarction, unstable angina, percutaneous coronary intervention [PCI], or coronary artery bypass grafting [CABG]).¹⁹⁴ The SOS study (Swedish

Obese Subjects), which is a nonrandomized prospective controlled study, also demonstrated a reduction of cardiovascular death in the bariatric surgery group compared with the control group.¹⁸⁵ To date, there is no randomized controlled trial on the effects of bariatric surgery on MACE incidence.

PCI and Obesity

Short-Term Outcomes After PCIs

The CathPCI Registry examined in-hospital complications of 83861 patients with severe obesity, including patients after myocardial infarction.¹⁹⁵ After multivariable adjustment, obesity was independently associated with a greater mortality rate and a lower bleeding rate.¹⁹⁵ Although obesity affects weight-based dosing protocols for unfractionated heparin, patients with severe obesity are underrepresented or even excluded from major trials.¹⁹⁶ A doubling in the time necessary to obtain adequate anticoagulation in patients weighing 110 kg with an initial infusion rate based on a nomogram was reported.¹⁹⁶ Another study of 227042 registry patients, including patients after myocardial infarction, with 37.2% (n=84479) having obesity and 7.4% (n=16730) having severe obesity,¹⁹⁷ reported that patients with severe obesity had significantly more contrast-induced nephropathy, nephropathy requiring dialysis, and vascular complications (almost exclusively femoral) compared with patients with overweight.¹⁹⁷ Gastrointestinal bleeding and MACE incidences were not statistically different. The British Cardiovascular Intervention Society Registry reported adverse in-hospital outcomes and mortality of 345192 patients undergoing PCI.¹⁹⁸ At 30 days after PCI, there was evidence of the obesity paradox, with lower mortality observed in patients with BMI ≥ 25 kg/m². Up to 5 years after PCI, BMI >25 kg/m² was an independent predictor of greater survival compared with normal weight, regardless of the clinical presentation (unstable angina, non-ST-segment-elevation myocardial infarction or ST-segment-elevation myocardial infarction).¹⁹⁸ The APPROACH registry (Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease) reported mortality in 30258 patients who had PCI and showed further evidence of the obesity paradox given that the 6-month mortality was lower in patients who were in the overweight or obese category compared with patients with normal BMI.¹⁹⁹

Long-Term Outcomes After PCIs

Patients with low BMI tend to have more events after PCI than patients with obesity.^{200,201} A study of 23181 patients from 11 prospective PCI studies used a BMI of 22.5 to 24.9 kg/m² as the reference category. The risk of major cardiovascular events was higher among patients with a lower BMI (<18.5 kg/m²) and declined among

patients with a higher BMI (>30.0 kg/m²).²⁰² A recent meta-analysis of 865774 patients undergoing PCI or CABG confirmed these findings and demonstrated a U-shaped association across all BMI categories for all-cause mortality and MACEs after PCI or CABG.²⁰³ This obesity paradox seems to wane when severe obesity is taken into consideration.^{199,204} The APPROACH registry demonstrated that the 5- and 10-year mortality rate after PCI in patients with class 3 obesity and high-risk coronary anatomy was higher than that of patients with normal BMI (odds ratio, 1.78 at 5 years and 1.57 at 10 years).¹⁹⁹

Antiplatelet Therapy in Obesity

Compared with patients with normal weight, individuals with obesity display higher platelet reactivity in a number of ex vivo assays of platelet function, including platelet aggregation.^{205,206} Adipose tissue produces multiple bioactive substances and hormones such as leptin, adiponectin, TNF- α (tumor necrosis factor- α), interleukin-6, and resistin, all of which may directly or indirectly affect platelet function.^{206,207} High levels of platelet aggregation and turnover are also found in patients with insulin resistance and hyperglycemia.²⁰⁸ High on-aspirin platelet reactivity is the laboratory-defined failure of aspirin to appropriately inhibit platelet thromboxane production or to inhibit platelet function. Several studies have linked obesity to an elevated risk of high on-aspirin platelet reactivity.²⁰⁹ In comparisons with individuals without obesity, postaspirin platelet reactivity was higher in the group with obesity at peak 1 hour after aspirin administration and trough 24 hours after aspirin administration time points.^{210,211} In a pharmacokinetic/pharmacodynamic comparison of aspirin formulations in patients with obesity and type 2 diabetes, high on-aspirin platelet reactivity was highest with enteric-coated aspirin because of the increase in esterase and phase II conjugation enzymes in obesity.²¹² Obesity-related endothelial dysfunction and persistent, low-grade inflammation can cause higher platelet consumption, leading to higher platelet turnover and acceleration of COX-1 (cyclooxygenase 1) renewal and resulting in a faster recovery of thromboxane-dependent platelet function and the loss of aspirin effect.^{213,214} Similar correlations between patients' BMI and residual platelet reactivity under treatment were observed with clopidogrel and prasugrel in patients with obesity. However, patients with obesity but without metabolic syndrome had a better response to thienopyridines compared with patients with obesity and metabolic syndrome and had a response similar to that of patients without obesity, suggesting that metabolic status is a better correlate of platelet inhibition than BMI.^{206,215} Some data suggest that patients with obesity receiving prasugrel had lower rates of high on-treatment platelet reactivity than those taking clopidogrel. However, a comparison of patients

with and without obesity on prasugrel revealed that 28% of patients with obesity had high on-treatment platelet reactivity compared with 4% of patients without obesity ($P < 0.01$). Although it seems that prasugrel is more effective in obesity compared with clopidogrel, it should be noted that additional data suggest that obesity might lead to a variable response effect to prasugrel compared with nonobesity.^{206,215} Conversely to thienopyridines, no correlation was reported between BMI and high on-treatment platelet reactivity with ticagrelor; patients with obesity do not express significantly higher levels of platelet reactivity, whereas ticagrelor seems to induce significantly higher platelet inhibition than prasugrel in patients with obesity.^{206,216} Although studies suggest that obesity may promote platelet activation and blunt effects of antiplatelet medications, clinical observations have pointed to an obesity paradox, namely that patients with obesity may have better post-acute coronary syndrome outcomes and may have a lower risk of reinfarction or death. Data involving platelet assays are often conflicting and involve sample sizes too small to draw decisive conclusions about clinical outcomes and to make recommendations about dosing adjustments of antiplatelet therapy in obesity.²⁰⁶

Surgical Revascularization

Obesity has been inconsistently associated with higher in-hospital mortality after CABG. An analysis of the Society of Thoracic Surgeons' database (559 004 patients who underwent isolated CABG between 1997 and 2000)²¹⁷ showed a higher risk of in-hospital mortality in patient with moderate obesity ($n=42\ 060$; BMI, 35–39.9 kg/m²) and patients with severe obesity ($n=18\ 735$; BMI >40 kg/m²) compared with patients with a BMI of 18.5 to 34.9 kg/m². These results contrasted with previous studies that found no significantly greater postoperative mortality in patients with obesity after CABG.^{218,219} A meta-analysis showed that the rate of in-hospital mortality after CABG was even less in the population with obesity.²²⁰ A potentially protective effect was also shown in a retrospective multicenter cohort study,²²¹ which showed that 30-day operative mortality was highest in extreme BMI groups (BMI <20 and >40 kg/m²) and lowest near a BMI of 30 kg/m², suggesting a U-shaped relationship.²²² Evidence on long-term mortality is still conflicting.¹⁷¹ A meta-analysis found decreased long-term mortality (1–5 years) for the population with overweight and obesity.^{203,220} In contrast, a recent retrospective study showed that obesity was associated with a higher rate of long-term mortality after CABG.²²³ Several studies have documented the association between obesity and numerous postoperative CABG complications such as renal failure,²²⁴ respiratory failure, arrhythmias, and greater intraoperative transfusion rate.^{27,225,226} In contrast, postoperative cerebrovascular events,

myocardial infarction, and postoperative bleeding do not appear to be higher in patients with obesity.^{225,226} A greater incidence of postoperative AF was reported in patients with obesity,²²⁷ as was a longer length of stay.¹⁹⁹ In a large cohort study of patients who underwent isolated CABG, WC was associated with a higher risk of postoperative AF, prolonged mechanical ventilation and reintubation, renal failure and new postoperative renal replacement therapy, bloodstream infection, sternal wound infections, and intensive care unit and hospital length of stay independently of BMI.²²⁸ Postoperative deep sternal wound infection is also more common in patients with obesity. CABG surgery using bilateral internal mammary artery instead of single internal mammary artery was associated with a higher risk of postoperative deep sternal wound infection without improving survival for patients with obesity.²²⁹ The large, poorly vascularized panniculus, the higher incidence of dysglycemia among those with obesity, and the difficulty in wound surveillance may predispose to wound infections.^{199,230} Obesity has also been identified as a risk factor for superficial wound infection and saphenous vein harvest site infection.²¹⁸

PATHOPHYSIOLOGY OF HF AND ARRHYTHMIAS IN OBESITY

Impact of Obesity on Heart Function

Excess adiposity promotes changes in cardiac function both directly through the effects on the myocardium and vasculature and indirectly through obesity-related comorbidities.²³¹ Excess adipose tissue accumulation leads to hemodynamic changes, including higher blood volume and cardiac output and a reduction in systemic vascular resistance.²⁷ Excess adiposity also leads to higher blood pressure as a result of activation of the renin-angiotensin-aldosterone and sympathetic nervous systems.²³² Obesity also directly affects the myocardium with myocardial fat accumulation and subsequent fibrosis that can lead to the development of LVDD and HF with preserved ejection fraction (HFpEF). Detailed phenotyping of patients with HFpEF with and without obesity compared with controls depicted that patients with obesity and HFpEF had greater concentric LV remodeling, right ventricular dilatation, and right ventricular dysfunction. There was also evidence of more pericardial restraint and ventricular interdependence for those with obesity and HFpEF in the setting of greater epicardial fat thickness and epicardial fat volume.^{233,234} Patients with obesity and HFpEF also had significantly lower exercise capacity compared with patients without obesity with HFpEF and control subjects. This was one of the first studies to demonstrate a distinct pathophysiological phenotype of HFpEF in the setting of obesity.²³³ Atherosclerotic heart disease related to obesity can lead






Figure 1. Pathophysiology of heart failure in obesity.

CVD indicates cardiovascular disease; and VLDL, very-low-density lipoprotein. Adapted from Rodriguez Flores et al²⁴⁰ with permission from Taylor & Francis Ltd (<https://www.tandfonline.com>). Copyright © 2017, Taylor & Francis Ltd.

to systolic dysfunction and, ultimately, HF with reduced ejection fraction (HFrEF). Finally, comorbidities associated with obesity such as diabetes, sleep apnea, and hypoventilation syndrome can increase the risk for pulmonary hypertension and right ventricular and LV failure.²³¹

Obesity and HF

Numerous studies have established obesity to be a major risk factor for hypertension, CVD, and LVH, all strong risk factors for the development of HF.^{177,178} In addition, obesity has potent adverse effects on LV systolic and, particularly, LV diastolic function. Multiple studies have established obesity as a major risk factor for the development of HF. In a study of 5881 Framingham Heart Study participants, HF incidence increased by 5% in men and 7% in women for every 1-unit BMI increase after adjustment for other risk factors, and the risk of HF increased across the entire spectrum of BMI.²³⁵ This was subsequently confirmed in several large, prospective epidemiological studies.^{235–237} Other anthropometric parameters of excess adiposity such as WC, WHR, and waist-to-height ratio have also been independently associated with HF risk, but they generally do not add substantive risk information for

HF beyond BMI measurement.^{236–239} Visceral obesity has a number of local effects on the myocardium, including inducing cardiomyocyte hypertrophy, myocardial fibrosis, and activation of inflammatory pathways relating to macrophage infiltration and cytokine gene expression. Excessive fat accumulation in VAT and ectopic sites such as the pericardium/epicardium and liver results in higher circulating blood volume and local and systemic proatherogenic inflammatory factors, which act to increase stroke volume, cardiac wall stress, and myocardial injury, leading to concentric LVH, LV remodeling, and ultimately diastolic and systolic cardiac failure (Figure 1).^{240–242} Recent work has also suggested that higher BMI is more strongly associated with the risk of HFpEF than with HFrEF.²⁴³ In fact, in a pooled analysis using data from 3 large longitudinal studies, Pandey et al²⁴⁴ demonstrated a greater association between higher BMI and risk of HFpEF, with participants with overweight and class 1 obesity having 38% and 56% higher risk of HFpEF, respectively, independently of other cardiovascular risk factors (Figure 2).²⁴⁴ Low fitness has been associated with a significantly higher risk of HF across all BMI categories and may explain close to 50% of HF risk associated with BMI.²⁴⁵




Figure 2. Association between body mass index and risk of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).

Reprinted from Pandey et al²⁴³ with permission from the American College of Cardiology Foundation. Copyright © 2018, American College of Cardiology Foundation.

Obesity and HF Outcomes

Data support the presence of the obesity paradox in HF: Patients with overweight or class 1 obesity have better clinical outcomes than patients with normal weight and similar degrees of HF, and this is seen more for HFrEF than for HFpEF.^{177–179} In addition, the protective effects of obesity on cardiovascular outcomes have now been noted for HFrEF, HFpEF, and acutely decompensated HF.^{177–179,237} This obesity paradox has also been noted for BMI, WC, and percent body fat,^{178,179,237,246,247} although a recent study in HFpEF suggested that higher WC was associated with better outcomes in univariate analysis but worse outcomes in multivariate analysis.^{248,249} Epicardial adipose tissue has recently been found to be low in patients with HF compared with the general population, and a recent study found that low epicardial adipose tissue in HF was associated with higher HF mortality, another aspect of the obesity paradox.^{237,250,251} Patients with obesity have lower levels of BNP (brain natriuretic peptide) than patients with normal weight, including in

HF.^{177,178,237} In patients with severe obesity, weight loss after bariatric surgery increases NT-proBNP (N-terminal pro-BNP) levels concomitantly with improved LVDD.²⁵² In advanced HF, extra adipose tissue and higher lean muscle mass may also provide reserves against cardiac cachexia and sarcopenia, which are associated with very poor cardiac prognosis in HF.^{253–255} However, the exact reasons why those who have overweight and mild obesity with less severe forms of HF are also protected are not entirely clear.^{177–179}

Obesity and Arrhythmias

There is now compelling evidence to support the importance of excess adiposity in determining arrhythmic risk, particularly focused on SCD and AF.^{256,257}

Obesity and SCD

There is an established association between obesity and SCD.^{258,259} Every 5-unit increment in BMI confers a 16% higher risk of SCD,²⁶⁰ and obesity has been identified as the most common nonischemic cause of SCD.²⁶¹ Data suggest that there may be an important role for body fat distribution, implicating abdominal adiposity as a marker of SCD.^{259,262} The potential mechanisms for this association are varied and may include LVH, QT prolongation, premature ventricular complexes, and autonomic imbalance.^{257,263,264} Both mild obesity and severe obesity are reported to be associated with greater risk of ventricular tachycardia (VT)/ventricular fibrillation (VF)^{265,266} and late potentials,²⁶⁷ highlighting a role in the formation of arrhythmic substrate. Clinical data reporting the substrate for VT/VF in obesity have come largely from autopsy studies, tissue Doppler, or endomyocardial biopsy. VT/VF in obesity is associated with increased LV diameter and mass,²⁶⁸ concentric LV hypertrophy,²⁶⁹ LVDD,^{268,270} and repolarization abnormalities. A common finding in obesity and obesity-mediated SCD is QRS fragmentation, a surrogate for heterogeneous conduction.^{271,272} Both QRS fragmentation²⁷³ and fibrosis²⁷⁴ are shown to be independent predictors of SCD, indicative of a potential role in mediating reentrant ventricular arrhythmias in obesity. Mechanistic studies from animal models have identified involvement of fibrosis, ion channel remodeling, and reduction of connexin proteins as likely drivers of lethal ventricular arrhythmias and SCD. In mice, rabbit, and rat models, high-fat diet has demonstrated (1) greater frequency of ventricular arrhythmias, attributed to oxidation RyR2 (ryanodine receptor type 2) and subsequently greater RyR2 calcium release; (2) changes in oxidative stress state, calcium handling, and putative components of the mitochondrial membrane permeability transition pore²⁷⁵; and (3) LVH and repolarization abnormalities.²⁷⁶ However, it remains to be determined whether these changes can be replicated in ventricles




Figure 3. Relationships between obesity and cardiac arrhythmias. AF indicates atrial fibrillation.

of models with established obesity. Epicardial adipose tissue was reported to be associated with higher occurrence of premature ventricular contractions, VT/VF,²⁷⁷ and all-cause long-term mortality²⁷⁷ and mortality from SCD.²⁷⁸ Furthermore, epicardial adipose tissue is significantly correlated with traditional SCD and VT/VF risk factors.^{63,65,279–281} In a post-myocardial infarction ovine model, intramyocardial adiposity and discontinuous conduction at scar borders were found to be associated with altered electrophysiological properties and higher propensity for VT.²⁸² Perhaps even more important, epicardial adipose tissue infiltrations and subsequent fibrosis (as shown in the atria) may drive reentrant circuits for lethal arrhythmias and SCD (Figure 3). Given that SCD is responsible for approximately half of all deaths resulting from CVD, obesity also represents a modifiable target to reduce the public health burden of SCD in our society. Also of clinical importance is that, in patients with obesity, the efficacy of chest compressions and airway protection may be compromised because of body habitus in case of sudden cardiac arrest, and the problem is likely to worsen as the patient's weight increases. Higher thoracic impedance associated with an increase in BMI may also reduce defibrillation success.^{283,284} It was shown that

severe obesity is associated with higher mortality after in-hospital cardiac arrest caused by either non-VF or VF arrest if it occurs late during hospitalization, and among survivors, discharge to home is significantly lower.²⁸⁵

Obesity and AF

Estimates suggest that obesity may account for one-fifth of AF cases and 60% of recently documented population increases.^{286–288} Weight gain and a higher midlife BMI are strongly correlated with incident AF in later life.^{289,290} Every 5-unit increment in BMI confers an $\approx 29\%$ greater risk of incident AF.²⁹¹ Moreover, these figures may underestimate the impact of adiposity when body fat distribution is considered. In addition, each 5-unit increment in BMI confers a 10% increase in postoperative AF and a 13% increase in postablation AF.²⁹¹ Progression of the disease has also been demonstrated in the context of obesity, with a BMI in the range of 30 to 34.9 kg/m² associated with a 54% increase in the likelihood of progression from paroxysmal to permanent AF and class 2 obesity (BMI 35.0 to 39.9 kg/m²) associated with an 87% increase in risk.²⁹² Overweight and obesity elevate the risk of AF through numerous mechanisms,

including structural and electric remodeling, which contribute to development of the arrhythmogenic substrate (Figure 3). Experimental studies in the ovine model have demonstrated short-term weight gain results in progressive remodeling of the atria, including a greater deposition of fibrous tissue, a greater expression of endothelin receptors, and abnormalities in atrial conduction, which in turn resulted in greater AF inducibility.²⁹³ A subsequent chronic ovine model of obesity extended these findings and described a unique component of the substrate for AF. This study demonstrated a marked increase in pericardial fat volumes. Histological samples of the atrial myocardium from regions adjacent to pericardial fat depots showed epicardial fat infiltrating the myocardium, potentially resulting in voltage abnormalities, conduction block, and higher AF vulnerability.²⁹⁴ Clinical data also demonstrate the role of obesity and epicardial fat in the promotion of AF. Early studies demonstrated that, compared with individuals with normal weight, patients with obesity undergoing electrophysiological studies were significantly more likely to have higher left atrial pressure and volumes.²⁹⁵ In addition, individuals with obesity had significant left atrial remodeling and impaired contractility. These features remained significant after adjustment for common cardiovascular risk factors such as hypertension, sleep apnea, and diabetes. More recently, a larger cohort who were undergoing AF ablation were studied with cardiac MRI and electroanatomic mapping of the left atrium before undergoing ablation.²⁹⁶ This study demonstrated that there was significantly more atrial remodeling, with areas of low voltage, conduction slowing, and increased fractionation of ECGs in patients with obesity. More distinct changes were noted in regions with greater epicardial fat depots, highlighting the role of epicardial fat in the promotion of AF. Epicardial adipose tissue has emerged as an important proarrhythmic substrate that may explain the excess risk of AF in obesity.^{296–298} The strength of associations of AF with epicardial fat is greater than for measures of abdominal and overall obesity, raising the possibility that adiposity may be more influential than previously suspected when quantified through BMI alone.²⁹⁹ The anatomic proximity of epicardial adipose tissue to the atrial myocardium lends credence to potential paracrine signaling.³⁰⁰ Mechanisms by which adiposity may lead to a susceptible electrophysiological substrate in the atria include fatty infiltration, adipokine-mediated fibrosis, LVDD, and inflammation, among many possibilities.³⁰¹

TREATMENT OF HF AND ARRHYTHMIAS IN OBESITY

Lifestyle Interventions in HF and Obesity

Currently, there is little evidence that weight reduction in HF leads to better major clinical outcomes or better

survival, but weight loss may reduce symptoms and improve quality of life and other medical conditions such as sleep apnea or diabetes.²³⁷ In addition, weight loss in advanced HF could improve the candidacy of patients with obesity for aggressive interventions such as LV assist device implantation and heart transplantation.^{240,302} Clearly, higher levels of physical activity and fitness have major impacts in reducing the development of HF,^{243–245} and in patients with established HF, high fitness is a major determinant of prognosis.^{177–179} Among patients with HF with preserved levels of fitness, several studies show a very good prognosis, regardless of BMI.^{177,178,237,303–305} Therefore, greater physical activity and exercise training, especially with the goal of improving fitness, are highly encouraged for individuals with obesity with HF. For elderly populations with obesity who may be at greatest risk for HF, more work is needed to develop effective strategies for maintaining weight and improving functional outcomes as opposed to weight loss interventions.

Medications for Weight Loss in HF

Although numerous medications are currently indicated for weight loss,^{177,237} only orlistat, a lipase inhibitor, has limited efficacy and safety for the treatment of obesity with HF.^{306,307} Several new classes of medications originally developed for patients with type 2 diabetes have shown promise for the treatment of both obesity and HF. Glucagon-like peptide agonists (at least liraglutide)^{191,308,309} and sodium-glucose cotransporter 2 inhibitors³¹⁰ have demonstrated efficacy for weight loss and reduced hospitalization for HF and cardiovascular death. Trials of these agents are currently ongoing, focusing on both patients with HFrEF and those with HFpEF with and without diabetes, with results forthcoming over the next 5 years. Recently, it was reported in individuals with overweight/obesity and HFrEF that the risk of worsening HF or cardiovascular death was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes.³¹¹

Obesity Management in Advanced HF

Advanced HF is typically considered a contraindication for bariatric surgery, but small studies of bariatric surgery have indicated improvements in LV function, myocardial mechanics, and functional classification among patients with HF with obesity.^{237,240,312} A recent retrospective study has also suggested that bariatric surgery reduces hospitalizations for HF in patients with a history of HF.³¹³ Although recent HF guidelines have not emphasized weight reduction, these guidelines recognize the high risk associated with severe obesity.^{237,314} Clearly, efforts to reduce obesity and, especially, to reduce the progression of obesity to class

2 or 3 levels are needed.¹⁷⁷ Class 3 obesity is a relative contraindication for heart transplantation because patients with obesity who undergo heart transplantation have higher acute rejections and higher 5-year mortality than patients with normal weight receiving heart transplantation.³⁰² However, obesity has not universally been considered a contraindication for LV assist device implantation,²⁴⁰ although there are adverse effects of obesity such as higher drive-line infection rates, and the clinical trials generally have excluded individuals with class 3 obesity. Clearly, there are opportunities to improve weight loss efforts in patients with an LV assist device with obesity who are anticipating heart transplantation, including a multidisciplinary approach with caloric restriction, physical activity/exercise training, and even bariatric surgery, that allow greater weight loss and greater ability to perform physical activity/exercise, allowing increases in muscle mass and function, possibly facilitating LV recovery, but certainly allowing the potential for better success with heart transplantation.³⁰²

Obesity Management and AF

Convincing data now demonstrate the benefits of weight loss in patients with AF, supporting a strong causative role for adiposity in these patients.³¹⁵ A randomized controlled trial of 150 individuals demonstrated that an intense weight loss and cardiometabolic risk factor management program resulted in a greater reduction in cumulative time in AF, symptom burden, and severity scores and beneficial cardiac remodeling, as evidenced by a reduction in interventricular septal dimension and left atrial area, after 15 months of follow-up.³¹⁶ This approach was further validated in a cohort study that resulted in an almost 5-fold higher likelihood of freedom from AF after ablation for those who attended this clinic compared with control subjects.³¹⁷ Concomitant improvements in numerous other cardiovascular risk factors were observed, including a reduction in blood pressure and improved lipid profiles, commensurate with weight reduction.³¹⁷ Long-term follow-up at 5 years demonstrated the sustainability of this approach, with individuals able to achieve a $\geq 10\%$ reduction in body weight and having an almost 6-fold higher likelihood of freedom from AF.³¹⁵ In addition, a reduced propensity for progression of the disease was observed, with greater degrees of weight loss associated with a reduced likelihood of progression to more permanent forms of the arrhythmia.³¹⁸ Collectively, these studies prove the dynamic nature of the AF substrate and solidify the role of cardiovascular risk factor management, in addition to rate and rhythm control and appropriate anticoagulation to mitigate stroke risk, as the essential fourth pillar of AF management.³¹⁹

Table 3. Summary of Recommendations for Future Research

| |
|--|
| Evaluation of lifestyle interventions with randomized controlled trials to identify the role of intentional weight loss and decreased visceral adiposity for improving CVD outcomes in obesity |
| Development of dietary interventions with large randomized controlled trials to identify healthful dietary patterns or personalized diets for CVD risk reduction in obesity |
| Development of upstream interventions for primary prevention and better treatment of obesity as a chronic disease among young patients with severe obesity |
| Identification of best practices for use of glucagon-like peptide agonists and sodium-glucose cotransporter 2 inhibitors to reduce hospitalization for HF and cardiovascular death for patients with HFrEF and HFpEF with and without diabetes |
| Development of effective strategies for weight maintenance and improved functional outcomes as opposed to weight loss interventions in elderly populations at risk for HF |

CVD indicates cardiovascular disease; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; and HFrEF, heart failure with reduced ejection fraction.

CONCLUSIONS

Obesity is recognized as a heterogeneous condition in which individuals with similar BMIs may have distinct metabolic and CVD risk profiles. Thus, susceptibility to obesity-related cardiovascular complications is not mediated solely by overall body fat mass but depends largely on individual differences in regional body fat distribution, which negatively affect cardiac structure and function. With increasing prevalence of obesity in populations with a longer life span, there is a need to evaluate mechanisms underlying obesity-related cardiac dysfunction and to improve the management of patients with obesity and CVD through future research (Table 3). In addition, the dramatic increase in the proportion of young patients with severe obesity invokes the need for more upstream interventions for the primary prevention and better treatment of obesity as a chronic disease.

ARTICLE INFORMATION

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on November 6, 2020, and the American Heart Association Executive Committee on December 16, 2020. A copy of the document is available at <https://professional.heart.org/statements> by using either "Search for Guidelines & Statements" or the "Browse by Topic" area. To purchase additional reprints, call 215-356-2721 or email Meredith.Edelman@wolterskluwer.com.

The American Heart Association requests that this document be cited as follows: Powell-Wiley TM, Poirier P, Burke LE, Després J-P, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, St-Onge M-P; on behalf of the American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2021;143:e●●●–e●●●. doi: 10.1161/CIR.0000000000000973.

The expert peer review of AHA-commissioned documents (eg, scientific statements, clinical practice guidelines, systematic reviews) is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit <https://professional.heart.org/statements>. Select the "Guidelines & Statements" drop-down menu, then click "Publication Development."

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission

are located at <https://www.heart.org/permissions>. A link to the "Copyright Permissions Request Form" appears in the second paragraph (<https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form>).

ACKNOWLEDGMENTS

The authors would like to acknowledge Ms Audrey Auclair and Ms Sam Neally for their assistance in formatting the scientific statement for publication.

Disclosures

Writing Group Disclosures

| Writing group member | Employment | Research grant | Other research support | Speakers' bureau/honoraria | Expert witness | Ownership interest | Consultant/advisory board | Other |
|-------------------------|---|--|------------------------|--|----------------|--|--|-------------------------------|
| Tiffany M. Powell-Wiley | National Institutes of Health | NIH (funded intramural investigator at NIH)† | None | None | None | None | None | None |
| Paul Poirier | Université Laval, Faculté de Pharmacie Institut Universitaire de Cardiologie et de Pneumologie de Québec (Canada) | None | None | Abbott*; Amgen*; AstraZeneca*; Bausch Health*; Bayer*; Boehringer Ingelheim*; Eli Lilly*; Janssen*; Novartis*; Novo Nordisk*; Sanofi*; Servier*; HLS Therapeutics* | None | None | Amgen*; Bausch Health*; Bayer*; Boehringer Ingelheim*; Eli Lilly*; Janssen*; Novartis*; Novo Nordisk*; Servier*; Sanofi* | None |
| Lora E. Burke | University of Pittsburgh | NIH† | None | None | None | None | None | NIH (principal investigator)† |
| Jean-Pierre Després | Université Laval, VITAM – Centre de recherche en santé durable (Canada) | Fondation IUCPQ-UL (coinvestigator)†; CIHR (PI)† | None | None | None | None | None  | None |
| Penny Gordon-Larsen | Gillings School of Global Public Health, University of North Carolina at Chapel Hill | NIH (principal investigator)*; NIH (coinvestigator)* | None | None | None | AstraZeneca (immediate family members)*; Amgen (immediate family members)*; Johnson & Johnson (immediate family members)*; Pfizer (immediate family members)*; Merck (immediate family members)* | NIDDK*; Boston Nutrition Obesity Research Center* | None |
| Carl J. Lavie | Ochsner Medical Center | None | None | AstraZeneca/FARXIGA* | None | None | AstraZeneca/FARXIGA* | None |
| Scott A. Lear | Simon Fraser University, St. Paul's Hospital (Canada) | Robert Wood Johnson Foundation†; Hamilton Health Sciences (research contract)† | None | None | None | None | None | None |
| Chiadi E. Ndumele | Johns Hopkins University | NIH (grant on mechanisms linking obesity to heart failure)† | None | None | None | None | None | None |
| Ian J. Neeland | University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine | NIH/NIDDK (K23 career development grant)† | None | None | None | None | Merck* | None |
| Prashanthan Sanders | University of Adelaide and Royal Adelaide Hospital (Australia) | None | None | None | None | None | None | None |
| Marie-Pierre St-Onge | Columbia University, Irving Medical Center | None | None | None | None | None | None | None |

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10,000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity or owns \$10,000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

*Modest.

†Significant.

Reviewer Disclosures

| Reviewer | Employment | Research grant | Other research support | Speakers' bureau/honoraria | Expert witness | Ownership interest | Consultant/advisory board | Other |
|-------------------------|---|---|------------------------|----------------------------|----------------|--------------------|---------------------------|-------|
| Leena P. Bharath | Merrimack College | None | None | None | None | None | None | None |
| Kevin P. Davy | Virginia Polytechnic Institute and State University | None | None | None | None | None | None | None |
| Francisco Lopez-Jimenez | Mayo Clinic | None | None | None | None | None | None | None |
| Eric D. Peterson | Duke Clinical Research Institute | Novo Nordisk*; AstraZeneca*; Janssen† | None | None | None | None | AstraZeneca*; Janssen* | None |
| Stephen Sidney | Kaiser Permanente | NHLBI (1RC2HL101666, relating to surveillance of cardiovascular disease, including stroke, in the Cardiovascular Research Network)†; NINDS (1U54NS081760-01, Stroke Prevention/Intervention Program [SPIRP])† | None | None | None | None | None | None |

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

*Modest.

†Significant.

REFERENCES

- Loos RJ. Genetic determinants of common obesity and their value in prediction. *Best Pract Res Clin Endocrinol Metab.* 2012;26:211–226. doi: 10.1016/j.beem.2011.11.003
- Gebreab SZ, Vandeleur CL, Rudaz D, Strippoli MF, Gholam-Rezaee M, Castela E, Lasserre AM, Glaus J, Pistis G, Kuehner C, et al. Psychosocial stress over the lifespan, psychological factors, and cardiometabolic risk in the community. *Psychosom Med.* 2018;80:628–639. doi: 10.1097/PSY.0000000000000621
- Sommer I, Griebler U, Mahlknecht P, Thaler K, Bouskill K, Gartlehner G, Mendis S. Socioeconomic inequalities in non-communicable diseases and their risk factors: an overview of systematic reviews. *BMC Public Health.* 2015;15:914. doi: 10.1186/s12889-015-2227-y
- Sallis JF, Glanz K. Physical activity and food environments: solutions to the obesity epidemic. *Milbank Q.* 2009;87:123–154. doi: 10.1111/j.1468-0009.2009.00550.x
- Franks PW, McCarthy MI. Exposing the exposures responsible for type 2 diabetes and obesity. *Science.* 2016;354:69–73. doi: 10.1126/science.aaf5094
- Jastreboff AM, Kotz CM, Kahan S, Kelly AS, Heymsfield SB. Obesity as a disease: The Obesity Society 2018 position statement. *Obesity (Silver Spring).* 2019;27:7–9. doi: 10.1002/oby.22378
- Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *Circulation.* 2014;129(suppl 2):S102–S138. doi: 10.1161/01.cir.0000437739.71477.ee
- Gordon-Larsen P, Heymsfield SB. Obesity as a disease, not a behavior. *Circulation.* 2018;137:1543–1545. doi: 10.1161/CIRCULATIONAHA.118.032780
- Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation on Obesity, Geneva, 3–5 June 1997. World Health Organization, Division of Noncommunicable Disease, Programme of Nutrition Family and Reproductive Health; 1998.
- Romero-Corral A, Somers VK, Sierra-Johnson J, Thomas RJ, Collazo-Clavell ML, Korinek J, Allison TG, Batsis JA, Sert-Kuniyoshi FH, Lopez-Jimenez F. Accuracy of body mass index in diagnosing obesity in the adult general population. *Int J Obes (Lond).* 2008;32:959–966. doi: 10.1038/ijo.2008.11
- Pack QR, Rodriguez-Escudero JP, Thomas RJ, Squires RW, Johnson L, Somers VK, Lopez-Jimenez F. Diagnostic performance of weight loss to predict body fatness improvement in cardiac rehabilitation patients. *J Cardiopulm Rehabil Prev.* 2013;33:68–76. doi: 10.1097/HCR.0b013e31827fe7e3
- Okorodudu DO, Jumean MF, Montori VM, Romero-Corral A, Somers VK, Erwin PJ, Lopez-Jimenez F. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. *Int J Obes (Lond).* 2010;34:791–799. doi: 10.1038/ijo.2010.5
- Heymsfield SB, Peterson CM, Thomas DM, Heo M, Schuna JM Jr. Why are there race/ethnic differences in adult body mass index-adiposity relationships? A quantitative critical review. *Obes Rev.* 2016;17:262–275. doi: 10.1111/obr.12358
- Rao G, Powell-Wiley TM, Ancheta I, Hairston K, Kirley K, Lear SA, North KE, Palaniappan L, Rosal MC; on behalf of the American Heart Association Obesity Committee of the Council on Lifestyle and Cardiometabolic Health. Identification of obesity and cardiovascular risk in ethnically and racially diverse populations: a scientific statement from the American Heart Association [published correction appears in *Circulation.* 2015;132:e130]. *Circulation.* 2015;132:457–472. doi: 10.1161/CIR.0000000000000223
- Zhou BF; Cooperative Meta-Analysis Group of the Working Group on Obesity in China. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults: study on optimal cut-off points of body mass index and waist circumference in Chinese adults. *Biomed Environ Sci.* 2002;15:83–96.
- Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, Marczak L, Mokdad AH, Moradi-Lakeh M, Naghavi M, et al; GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. *N Engl J Med.* 2017;377:13–27.
- Maffettone PB, Rivera-Dominguez I, Laursen PB. Overfat and underfat: new terms and definitions long overdue. *Front Public Health.* 2017;4:e00279. doi: 10.3389/fpubh.2016.00279
- Di Angelantonio E, Bhupathiraju SN, Wormser D, Gao P, Kaptoge S, de Gonzalez AB, Cairns BJ, Huxley R, Jackson CL, Joshy G, et al; Global BMI Mortality Collaboration. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. *Lancet.* 2016;388:776–786.
- Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. *JAMA.* 2016;315:2284–2291. doi: 10.1001/jama.2016.6458
- Beccia AL, Jesdale WM, Lapane KL. Associations between perceived everyday discrimination, discrimination attributions, and binge eating among Latinas: results from the National Latino and Asian American Study. *Ann Epidemiol.* 2020;45:32–39. doi: 10.1016/j.annepidem.2020.03.012

21. Cozier YC, Yu J, Coogan PF, Bethea TN, Rosenberg L, Palmer JR. Racism, segregation, and risk of obesity in the Black Women's Health Study. *Am J Epidemiol*. 2014;179:875–883. doi: 10.1093/aje/kwu004
22. Wu YK, Berry DC, Schwartz TA. Weight stigmatization and binge eating in Asian Americans with overweight and obesity. *Int J Env Res Public Health*. 2020;17:4319. doi: 10.3390/ijerph17124319
23. Cuevas AG, Chen R, Slopen N, Thurber KA, Wilson N, Economos C, Williams DR. Assessing the role of health behaviors, socioeconomic status, and cumulative stress for racial/ethnic disparities in obesity. *Obesity (Silver Spring)*. 2020;28:161–170. doi: 10.1002/oby.22648
24. Bell CN, Kerr J, Young JL. Associations between Obesity, Obesogenic Environments, and Structural Racism Vary by County-Level Racial Composition. *Int J Env Res Public Health*. 2019;16:861. doi: 10.3390/ijerph16050861
25. Chen Y, Freedman ND, Albert PS, Huxley RR, Shiels MS, Withrow DR, Spillane S, Powell-Wiley TM, Berrington de González A. Association of cardiovascular disease with premature mortality in the United States. *JAMA Cardiol*. 2019;4:1230–1238. doi: 10.1001/jamacardio.2019.3891
26. Cardel MI, Atkinson MA, Taveras EM, Holm JC, Kelly AS. Obesity treatment among adolescents: a review of current evidence and future directions. *JAMA Pediatr*. 2020;174:609–617. doi: 10.1001/jamapediatrics.2020.0085
27. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association scientific statement on obesity and heart disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. *Circulation*. 2006;113:898–918. doi: 10.1161/CIRCULATIONAHA.106.171016
28. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. *J Thromb Thrombolysis*. 2016;41:3–14. doi: 10.1007/s11239-015-1311-6
29. Rahmani J, Roudsari AH, Bawadi H, Thompson J, Fard RK, Clark C, Ryan PM, Ajami M, Sakak FR, Salehisahlabadi A, et al. Relationship between body mass index, risk of venous thromboembolism and pulmonary embolism: a systematic review and dose-response meta-analysis of cohort studies among four million participants. *Thromb Res*. 2020;192:64–72. doi: 10.1016/j.thromres.2020.05.014
30. Gómez-Ambrosi J, Silva C, Galofré JC, Escalada J, Santos S, Millán D, Vila N, Ibañez P, Gil MJ, Valentí V, et al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. *Int J Obes (Lond)*. 2012;36:286–294. doi: 10.1038/ijo.2011.100
31. Romero-Corral A, Somers VK, Sierra-Johnson J, Korenfeld Y, Boarin S, Korinek J, Jensen MD, Parati G, Lopez-Jimenez F. Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. *Eur Heart J*. 2010;31:737–746. doi: 10.1093/eurheartj/ehp487
32. Batsis JA, Sahakyan KR, Rodriguez-Escudero JP, Bartels SJ, Somers VK, Lopez-Jimenez F. Normal weight obesity and mortality in United States subjects ≥ 60 years of age (from the Third National Health and Nutrition Examination Survey). *Am J Cardiol*. 2013;112:1592–1598. doi: 10.1016/j.amjcard.2013.07.014
33. Piché ME, Poirier P, Lemieux I, Després JP. Overview of epidemiology and contribution of obesity and body fat distribution to cardiovascular disease: an update. *Prog Cardiovasc Dis*. 2018;61:103–113. doi: 10.1016/j.pcad.2018.06.004
34. Sahakyan KR, Somers VK, Rodriguez-Escudero JP, Hodge DO, Carter RE, Sochor O, Coutinho T, Jensen MD, Roger VL, Singh P, et al. Normal-weight central obesity: implications for total and cardiovascular mortality. *Ann Intern Med*. 2015;163:827–835. doi: 10.7326/M14-2525
35. Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, Kushner RF, Daniels SR, Wadden TA, Tsai AG, et al. The science of obesity management: an Endocrine Society scientific statement. *Endocr Rev*. 2018;39:79–132. doi: 10.1210/er.2017-00253
36. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive clinical practice guidelines For medical care of patients with obesity. *Endocr Pract*. 2016;22(suppl 3):1–203. doi: 10.4158/EP161365.GL
37. Shah RV, Murthy VL, Abbasi SA, Blankstein R, Kwong RY, Goldfine AB, Jeresch-Herold M, Lima JAC, Ding JZ, Allison MA, et al. Visceral adiposity and the risk of metabolic syndrome across body mass index: the MESA study. *J Am Coll Cardiol Cardiovasc Imag*. 2014;7:1222–1235. doi: 10.1016/j.jcmg.2014.07.017
38. Abraham TM, Pedley A, Massaro JM, Hoffmann U, Fox CS. Association between visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors. *Circulation*. 2015;132:1639–1647. doi: 10.1161/CIRCULATIONAHA.114.015000
39. Tatsumi Y, Nakao YM, Masuda I, Higashiyama A, Takegami M, Nishimura K, Watanabe M, Ohkubo T, Okamura T, Miyamoto Y. Risk for metabolic diseases in normal weight individuals with visceral fat accumulation: a cross-sectional study in Japan. *BMJ Open*. 2017;7:e013831. doi: 10.1136/bmjopen-2016-013831
40. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, Vasan RS, Murabito JM, Meigs JB, Cupples LA, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. *Circulation*. 2007;116:39–48. doi: 10.1161/CIRCULATIONAHA.106.675355
41. Neeland IJ, Ayers CR, Rohatgi AK, Turer AT, Berry JD, Das SR, Vega GL, Khera A, McGuire DK, Grundy SM, et al. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. *Obesity (Silver Spring)*. 2013;21:E439–E447. doi: 10.1002/oby.20135
42. Neeland IJ, Poirier P, Després JP. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. *Circulation*. 2018;137:1391–1406. doi: 10.1161/CIRCULATIONAHA.117.029617
43. Nazare JA, Smith J, Borel AL, Aschner P, Barter P, Van Gaal L, Tan CE, Wittchen HU, Matsuzawa Y, Kadowaki T, et al. Usefulness of measuring both body mass index and waist circumference for the estimation of visceral adiposity and related cardiometabolic risk profile (from the INSPIRE ME IAA Study). *Am J Cardiol*. 2015;115:307–315. doi: 10.1016/j.amjcard.2014.10.039
44. Lee JJ, Pedley A, Hoffmann U, Massaro JM, Levy D, Long MT. Visceral and intrahepatic fat are associated with cardiometabolic risk factors above other ectopic fat depots: the Framingham Heart Study. *Am J Med*. 2018;131:684–692.e12. doi: 10.1016/j.amjmed.2018.02.002
45. Ross R, Bradshaw AJ. The future of obesity reduction: beyond weight loss. *Nat Rev Endocrinol*. 2009;5:319–325. doi: 10.1038/nrendo.2009.78
46. Després JP. Body fat distribution and risk of cardiovascular disease: an update. *Circulation*. 2012;126:1301–1313. doi: 10.1161/CIRCULATIONAHA.111.067264
47. Hiuge-Shimizu A, Kishida K, Funahashi T, Ishizaka Y, Oka R, Okada M, Suzuki S, Takaya N, Nakagawa T, Fukui T, et al. Absolute value of visceral fat area measured on computed tomography scans and obesity-related cardiovascular risk factors in large-scale Japanese general population (the VACATION-J study). *Ann Med*. 2012;44:82–92. doi: 10.3109/07853890.2010.526138
48. Després JP. What is “metabolically healthy obesity”? From epidemiology to pathophysiological insights. *J Clin Endocrinol Metab*. 2012;97:2283–2285. doi: 10.1210/jc.2012-2081
49. Camhi SM, Must A, Gona PN, Hankinson A, Odegaard A, Reis J, Gunderson EP, Jacobs DR, Carnethon MR. Duration and stability of metabolically healthy obesity over 30 years. *Int J Obes (Lond)*. 2019;43:1803–1810. doi: 10.1038/s41366-018-0197-8
50. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. *Nature*. 2006;444:881–887. doi: 10.1038/nature05488
51. Britton KA, Massaro JM, Murabito JM, Kregar BE, Hoffmann U, Fox CS. Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. *J Am Coll Cardiol*. 2013;62:921–925. doi: 10.1016/j.jacc.2013.06.027
52. Mongraw-Chaffin M, Allison MA, Burke GL, Criqui MH, Matsushita K, Ouyang P, Shah RV, Shay CM, Anderson CAM. CT-derived body fat distribution and incident cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. *J Clin Endocrinol Metab*. 2017;102:4173–4183. doi: 10.1210/jc.2017-01113
53. Neeland IJ, Turer AT, Ayers CR, Berry JD, Rohatgi A, Das SR, Khera A, Vega GL, McGuire DK, Grundy SM, de Lemos JA. Body fat distribution and incident cardiovascular disease in obese adults. *J Am Coll Cardiol*. 2015;65:2150–2151. doi: 10.1016/j.jacc.2015.01.061
54. Guerrero R, Vega GL, Grundy SM, Browning JD. Ethnic differences in hepatic steatosis: an insulin resistance paradox? *Hepatology*. 2009;49:791–801. doi: 10.1002/hep.22726
55. Nazare JA, Smith JD, Borel AL, Haffner SM, Balkau B, Ross R, Massien C, Alméras N, Després JP. Ethnic influences on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and cardiometabolic risk profile: the International Study of Prediction of Intra-Abdominal Adiposity and Its Relationship With Cardiometabolic Risk/Intra-Abdominal Adiposity. *Am J Clin Nutr*. 2012;96:714–726. doi: 10.3945/ajcn.112.035758

56. Lim S, Taskinen MR, Borén J. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome. *Obes Rev*. 2019;20:599–611. doi: 10.1111/obr.12820
57. Klein S. Is visceral fat responsible for the metabolic abnormalities associated with obesity? Implications of omentectomy. *Diabetes Care*. 2010;33:1693–1694. doi: 10.2337/dc10-0744
58. Lauridsen BK, Stender S, Kristensen TS, Kofoed KF, Køber L, Nordestgaard BG, Tybjaerg-Hansen A. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals. *Eur Heart J*. 2018;39:385–393. doi: 10.1093/eurheartj/ehx662
59. Adiels M, Olofsson SO, Taskinen MR, Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. *Arterioscler Thromb Vasc Biol*. 2008;28:1225–1236. doi: 10.1161/ATVBAHA.107.160192
60. Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. *Nat Rev Gastroenterol Hepatol*. 2017;14:32–42. doi: 10.1038/nrgastro.2016.147
61. Ndumele CE, Nasir K, Conceição RD, Carvalho JA, Blumenthal RS, Santos RD. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. *Arterioscler Thromb Vasc Biol*. 2011;31:1927–1932. doi: 10.1161/ATVBAHA.111.228262
62. Iacobellis G. Epicardial and pericardial fat: close, but very different. *Obesity (Silver Spring)*. 2009;17:625; author reply 626; author reply 627. doi: 10.1038/oby.2008.575
63. Mahabadi AA, Massaro JM, Rosito GA, Levy D, Murabito JM, Wolf PA, O'Donnell CJ, Fox CS, Hoffmann U. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. *Eur Heart J*. 2009;30:850–856. doi: 10.1093/eurheartj/ehn573
64. Ong KL, Ding J, McClelland RL, Cheung BM, Criqui MH, Barter PJ, Rye KA, Allison MA. Relationship of pericardial fat with lipoprotein distribution: the Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis*. 2015;241:664–670. doi: 10.1016/j.atherosclerosis.2015.06.027
65. Shah RV, Anderson A, Ding JZ, Budoff M, Rider O, Petersen SE, Jensen MK, Koch M, Allison M, Kawel-Boehm N, et al. Pericardial, but not hepatic, fat by CT is associated with cv outcomes and structure: the Multi-Ethnic Study of Atherosclerosis. *JACC Cardiovasc Imag*. 2017;10:1016–1027. doi: 10.1016/j.jcmg.2016.10.024
66. Larsen BA, Laughlin GA, Saad SD, Barrett-Connor E, Allison MA, Wassel CL. Pericardial fat is associated with all-cause mortality but not incident CVD: the Rancho Bernardo Study. *Atherosclerosis*. 2015;239:470–475. doi: 10.1016/j.atherosclerosis.2015.02.022
67. Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. *Nat Rev Endocrinol*. 2015;11:363–371. doi: 10.1038/nrendo.2015.58
68. Hruskova J, Mauerer A, Podrouzkova H, Stipalova T, Jakubik J, Barchitta M, Medina-Inojosa JR, Homolka M, Agodi A, Kunzova S, et al. Association of cardiovascular health with epicardial adipose tissue and intima media thickness: the KardioVize study. *J Clin Med*. 2018;7:113. doi: 10.3390/jcm7050113
69. Al-Talabany S, Mordi I, Graeme Houston J, Colhoun HM, Weir-McCall JR, Matthew SZ, Looker HC, Levin D, Belch JFF, Dove F, et al. Epicardial adipose tissue is related to arterial stiffness and inflammation in patients with cardiovascular disease and type 2 diabetes. *BMC Cardiovasc Disord*. 2018;18:31. doi: 10.1186/s12872-018-0770-z
70. Iacobellis G, Ribaudo MC, Assael F, Vecci E, Tiberti C, Zappaterreno A, Di Mario U, Leonetti F. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. *J Clin Endocrinol Metab*. 2003;88:5163–5168. doi: 10.1210/jc.2003-030698
71. Akilli H, Kayrak M, Bekci TT, Erdogan HI, Aribas A, Yildirim O, Taner A, Erer M, Unlu A. Gender-related changes of the epicardial fat thickness and leptin in obstructive sleep apnea. *Echocardiography*. 2014;31:411–419. doi: 10.1111/echo.12392
72. St-Onge MP, Grandner MA, Brown D, Conroy MB, Jean-Louis G, Coons M, Bhatt DL; on behalf of the American Heart Association Obesity, Behavior Change, Diabetes, and Nutrition Committees of the Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Sleep duration and quality: impact on lifestyle behaviors and cardiometabolic health: a scientific statement from the American Heart Association. *Circulation*. 2016;134:e367–e386. doi: 10.1161/CIR.0000000000000444
73. Ng SS, Liu EK, Ma RC, Chan TO, To KW, Chan KK, Ngai J, Yip WH, Ko FW, Wong CK, et al. Effects of CPAP therapy on visceral fat thickness, carotid intima-media thickness and adipokines in patients with obstructive sleep apnoea. *Respirology*. 2017;22:786–792. doi: 10.1111/resp.12963
74. Sivam S, Phillips CL, Trenell MI, Yee BJ, Liu PY, Wong KK, Grunstein RR. Effects of 8 weeks of continuous positive airway pressure on abdominal adiposity in obstructive sleep apnoea. *Eur Respir J*. 2012;40:913–918. doi: 10.1183/09031936.00177011
75. Fujimoto WY, Jablonski KA, Bray GA, Kriska A, Barrett-Connor E, Haffner S, Hanson R, Hill JO, Hubbard V, Stamm E, et al; Diabetes Prevention Program Research Group. Body size and shape changes and the risk of diabetes in the Diabetes Prevention Program. *Diabetes*. 2007;56:1680–1685. doi: 10.2337/db07-0009
76. Rao S, Pandey A, Garg S, Park B, Mayo H, Després JP, Kumbhani D, de Lemos JA, Neeland IJ. Effect of exercise and pharmacological interventions on visceral adiposity: a systematic review and meta-analysis of long-term randomized controlled trials. *Mayo Clin Proc*. 2019;94:211–224. doi: 10.1016/j.mayocp.2018.09.019
77. Ross R, Dagnone D, Jones PJ, Smith H, Paddags A, Hudson R, Janssen I. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men: a randomized, controlled trial. *Ann Intern Med*. 2000;133:92–103. doi: 10.7326/0003-4819-133-2-200007180-00008
78. Ross R, Janssen I, Dawson J, Kungl AM, Kuk JL, Wong SL, Nguyen-Duy TB, Lee S, Kilpatrick K, Hudson R. Exercise-induced reduction in obesity and insulin resistance in women: a randomized controlled trial. *Obes Res*. 2004;12:789–798. doi: 10.1038/oby.2004.95
79. Boudou P, de Kerviler E, Erlich D, Vexiau P, Gautier JF. Exercise training-induced triglyceride lowering negatively correlates with DHEA levels in men with type 2 diabetes. *Int J Obes Relat Metab Disord*. 2001;25:1108–1112. doi: 10.1038/sj.ijo.0801637
80. Verheggen RJ, Maessen MF, Green DJ, Hermus AR, Hopman MT, Thijssen DH. A systematic review and meta-analysis of the effects of exercise training versus hypocaloric diet: distinct effects on body weight and visceral adipose tissue. *Obes Rev*. 2016;17:664–690. doi: 10.1111/obr.12406
81. Cruz P, Johnson BD, Karpinski SC, Limoges KA, Warren BA, Olsen KD, Somers VK, Jensen MD, Clark MM, Lopez-Jimenez F. Validity of weight loss to estimate improvement in body composition in individuals attending a wellness center. *Obesity (Silver Spring)*. 2011;19:2274–2279. doi: 10.1038/oby.2011.102
82. Lesser IA, Singer J, Hoogbruin A, Mackey DC, Katzmarzyk PT, Sohal P, Leipsic J, Lear SA. Effectiveness of exercise on visceral adipose tissue in older South Asian women. *Med Sci Sports Exerc*. 2016;48:1371–1378. doi: 10.1249/MSS.0000000000000906
83. Cooper JH, Collins BE, Adams DR, Robergs RA, Donges CE. Limited effects of endurance or interval training on visceral adipose tissue and systemic inflammation in sedentary middle-aged men. *J Obes*. 2016;2016:2479597. doi: 10.1155/2016/2479597
84. Hintze LJ, Messier V, Lavoie MÈ, Brochu M, Lavoie JM, Prud'homme D, Rabasa-Lhoret R, Doucet É. A one-year resistance training program following weight loss has no significant impact on body composition and energy expenditure in postmenopausal women living with overweight and obesity. *Physiol Behav*. 2018;189:99–106. doi: 10.1016/j.physbeh.2018.03.014
85. Slentz CA, Bateman LA, Willis LH, Shields AT, Tanner CJ, Piner LW, Hawk VH, Muehlbauer MJ, Samsa GP, Nelson RC, et al. Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT/RT. *Am J Physiol Endocrinol Metab*. 2011;301:E1033–E1039. doi: 10.1152/ajpendo.00291.2011
86. Maillard F, Rousset S, Pereira B, Traore A, de Pradel Del Amaze P, Boirie Y, Duclos M, Boisseau N. High-intensity interval training reduces abdominal fat mass in postmenopausal women with type 2 diabetes. *Diabetes Metab*. 2016;42:433–441. doi: 10.1016/j.diabet.2016.07.031
87. Zhang H, Tong TK, Qiu W, Zhang X, Zhou S, Liu Y, He Y. Comparable effects of high-intensity interval training and prolonged continuous exercise training on abdominal visceral fat reduction in obese young women. *J Diabetes Res*. 2017;2017:5071740. doi: 10.1155/2017/5071740
88. Herzig KH, Ahola R, Leppäloueto J, Jokelainen J, Jämsä T, Keinänen-Kiukaanniemi S. Light physical activity determined by a motion sensor decreases insulin resistance, improves lipid homeostasis and reduces visceral fat in high-risk subjects: PreDiabEx study RCT. *Int J Obes (Lond)*. 2014;38:1089–1096. doi: 10.1038/ijo.2013.224

89. Friedenreich CM, Neilson HK, O'Reilly R, Duha A, Yasui Y, Morielli AR, Adams SC, Courneya KS. Effects of a high vs moderate volume of aerobic exercise on adiposity outcomes in postmenopausal women: a randomized clinical trial. *JAMA Oncol.* 2015;1:766–776. doi: 10.1001/jamaoncol.2015.2239
90. van Gemert WA, Peeters PH, May AM, Doornbos AJH, Elias SG, van der Palen J, Veldhuis W, Stapper M, Schuit JA, Monnikhof EM. Effect of diet with or without exercise on abdominal fat in postmenopausal women: a randomised trial. *BMC Public Health.* 2019;19:174. doi: 10.1186/s12889-019-6510-1
91. Trussardi Fayh AP, Lopes AL, Fernandes PR, Reischak-Oliveira A, Friedman R. Impact of weight loss with or without exercise on abdominal fat and insulin resistance in obese individuals: a randomised clinical trial. *Br J Nutr.* 2013;110:486–492. doi: 10.1017/S0007114512005442
92. Murphy JC, McDaniel JL, Mora K, Villareal DT, Fontana L, Weiss EP. Preferential reductions in intermuscular and visceral adipose tissue with exercise-induced weight loss compared with calorie restriction. *J Appl Physiol (1985).* 2012;112:79–85. doi: 10.1152/jappphysiol.00355.2011
93. Giannopoulou I, Ploutz-Snyder LL, Carhart R, Weinstock RS, Fernhall B, Gouloupoulos S, Kanaley JA. Exercise is required for visceral fat loss in postmenopausal women with type 2 diabetes. *J Clin Endocrinol Metab.* 2005;90:1511–1518. doi: 10.1210/jc.2004-1782
94. Pedersen LR, Olsen RH, Jürs A, Astrup A, Chabanova E, Simonsen L, Wislaff U, Haugaard SB, Prescott E. A randomised trial comparing weight loss with aerobic exercise in overweight individuals with coronary artery disease: the CUTIT trial. *Eur J Prev Cardiol.* 2015;22:1009–1017. doi: 10.1177/2047487314545280
95. Gallagher D, Heshka S, Kelley DE, Thornton J, Boxt L, Pi-Sunyer FX, Patricio J, Mancino J, Clark JM; MRI Ancillary Study Group of Look AHEAD Research Group. Changes in adipose tissue depots and metabolic markers following a 1-year diet and exercise intervention in overweight and obese patients with type 2 diabetes. *Diabetes Care.* 2014;37:3325–3332. doi: 10.2337/dc14-1585
96. Keating SE, Hackett DA, Parker HM, O'Connor HT, Gerofi JA, Sainsbury A, Baker MK, Chuter VH, Caterson ID, George J, et al. Effect of aerobic exercise training dose on liver fat and visceral adiposity. *J Hepatol.* 2015;63:174–182. doi: 10.1016/j.jhep.2015.02.022
97. Zhang HJ, Pan LL, Ma ZM, Chen Z, Huang ZF, Sun Q, Lu Y, Han CK, Lin MZ, Li XJ, et al. Long-term effect of exercise on improving fatty liver and cardiovascular risk factors in obese adults: a 1-year follow-up study. *Diabetes Obes Metab.* 2017;19:284–289. doi: 10.1111/dom.12809
98. Fernandez-del-Valle M, Gonzales JU, Kloiber S, Mitra S, Klingensmith J, Larumbe-Zabala E. Effects of resistance training on MRI-derived epicardial fat volume and arterial stiffness in women with obesity: a randomized pilot study. *Eur J Appl Physiol.* 2018;118:1231–1240. doi: 10.1007/s00421-018-3852-9
99. Honkala SM, Motiani KK, Eskelinen JJ, Savolainen A, Saunavaara V, Virtanen KA, Löytyniemi E, Kapanen J, Knuuti J, Kalliokoski KK, et al. Exercise training reduces intrathoracic fat regardless of effective glucose tolerance. *Med Sci Sports Exerc.* 2017;49:1313–1322. doi: 10.1249/MSS.0000000000001232
100. Rabkin SW, Campbell H. Comparison of reducing epicardial fat by exercise, diet or bariatric surgery weight loss strategies: a systematic review and meta-analysis. *Obes Rev.* 2015;16:406–415. doi: 10.1111/obr.12270
101. Yoshimura E, Kumahara H, Tobina T, Matsuda T, Ayabe M, Kiyonaga A, Anzai K, Higaki Y, Tanaka H. Lifestyle intervention involving calorie restriction with or without aerobic exercise training improves liver fat in adults with visceral adiposity. *J Obes.* 2014;2014:197216. doi: 10.1155/2014/197216
102. Brinkley TE, Ding J, Carr JJ, Nicklas BJ. Pericardial fat loss in postmenopausal women under conditions of equal energy deficit. *Med Sci Sports Exerc.* 2011;43:808–814. doi: 10.1249/MSS.0b013e3181fb512d
103. Hsieh SD, Yoshinaga H. Abdominal fat distribution and coronary heart disease risk factors in men: waist/height ratio as a simple and useful predictor. *Int J Obesity.* 1995;19:585–589.
104. Ashwell M, Gibson S. Waist-to-height ratio as an indicator of “early health risk”: simpler and more predictive than using a “matrix” based on BMI and waist circumference. *BMJ Open.* 2016;6:e010159. doi: 10.1136/bmjopen-2015-010159
105. Coutinho T, Goel K, de Sa DC, Carter RE, Hodge DO, Kragelund C, Kanaya AM, Zeller M, Park JS, Kober L, et al. Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of “normal weight central obesity.” *J Am Coll Cardiol.* 2013;61:553–560. doi: 10.1016/j.jacc.2012.10.035
106. McGill HC Jr. Fatty streaks in the coronary arteries and aorta. *Lab Invest.* 1968;18:560–564.
107. Strong JP, Malcom GT, McMahan CA, Tracy RE, Newman WP 3rd, Herderick EE, Cornhill JF. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. *JAMA.* 1999;281:727–735. doi: 10.1001/jama.281.8.727
108. McGill HC Jr, McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE, Strong JP; for the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Obesity accelerates the progression of coronary atherosclerosis in young men. *Circulation.* 2002;105:2712–2718. doi: 10.1161/01.cir.0000018121.67607.ce
109. Berenson GS, Srinivasan SR, Bao WH, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. *N Engl J Med.* 1998;338:1650–1656. doi: 10.1056/NEJM199806043382302
110. McGill HC Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP, Wissler RW, Robertson AL, Cornhill JF, Gay S, Gay RE, et al. Relation of glycohemoglobin and adiposity to atherosclerosis in youth. *Arterioscler Thromb Vasc Biol.* 1995;15:431–440. doi: 10.1161/01.atv.15.4.431
111. Zieske AW, Malcom GT, Strong JP. Natural history and risk factors of atherosclerosis in children and youth: the PDAY study. *Pediatr Pathol Mol Med.* 2002;21:213–237. doi: 10.1080/15227950252852104
112. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. *Nat Rev Cardiol.* 2009;6:399–409. doi: 10.1038/nrcardio.2009.55
113. Ross R. Atherosclerosis is an inflammatory disease. *Am Heart J.* 1999;138(pt 2):S419–S420. doi: 10.1016/s0002-8703(99)70266-8
114. Couillard C, Ruel G, Archer WR, Pomerleau S, Bergeron J, Couture P, Lamarche B, Bergeron N. Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. *J Clin Endocrinol Metab.* 2005;90:6454–6459. doi: 10.1210/jc.2004-2438
115. Grundy SM. Metabolic syndrome update. *Trends Cardiovasc Med.* 2016;26:364–373. doi: 10.1016/j.tcm.2015.10.004
116. Engin A. Endothelial dysfunction in obesity. *Adv Exp Med Biol.* 2017;960:345–379. doi: 10.1007/978-3-319-48382-5_15
117. De Michele M, Panico S, Iannuzzi A, Celentano E, Ciardullo AV, Galasso R, Sacchetti L, Zarrilli F, Bond MG, Rubba P. Association of obesity and central fat distribution with carotid artery wall thickening in middle-aged women. *Stroke.* 2002;33:2923–2928. doi: 10.1161/01.str.0000038989.90931.be
118. Freedman DS, Dietz WH, Tang R, Mensah GA, Bond MG, Urbina EM, Srinivasan S, Berenson GS. The relation of obesity throughout life to carotid intima-media thickness in adulthood: the Bogalusa Heart Study. *Int J Obes Relat Metab Disord.* 2004;28:159–166. doi: 10.1038/sj.ijo.0802515
119. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. *N Engl J Med.* 1999;341:1097–1105. doi: 10.1056/NEJM199910073411501
120. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. *Circulation.* 1983;67:968–977. doi: 10.1161/01.cir.67.5.968
121. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE. Body weight and mortality among women. *N Engl J Med.* 1995;333:677–685. doi: 10.1056/NEJM199509143331101
122. Folsom AR, Stevens J, Schreiner PJ, McGovern PG. Body mass index, waist/hip ratio, and coronary heart disease incidence in African Americans and Whites: Atherosclerosis Risk in Communities Study Investigators. *Am J Epidemiol.* 1998;148:1187–1194. doi: 10.1093/oxfordjournals.aje.a009608
123. Bogers RP, Bemelmans WJ, Hoogenveen RT, Boshuizen HC, Woodward M, Knekt P, van Dam RM, Hu FB, Visscher TL, Menotti A, et al; BMI-CHD Collaboration Investigators. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. *Arch Intern Med.* 2007;167:1720–1728. doi: 10.1001/archinte.167.16.1720
124. Canoy D, Cairns BJ, Balkwill A, Wright FL, Green J, Reeves G, Beral V; Million Women Study Collaborators. Coronary heart disease incidence in women by waist circumference within categories of body mass index. *Eur J Prev Cardiol.* 2013;20:759–762. doi: 10.1177/2047487313492631
125. Zhang C, Rexrode KM, van Dam RM, Li TY, Hu FB. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. *Circulation.* 2008;117:1658–1667. doi: 10.1161/CIRCULATIONAHA.107.739714

126. Reis JP, Allen N, Gunderson EP, Lee JM, Lewis CE, Loria CM, Powell-Wiley TM, Rana JS, Sidney S, Wei G, et al. Excess body mass index- and waist circumference-years and incident cardiovascular disease: the CARDIA study. *Obesity (Silver Spring)*. 2015;23:879–885. doi: 10.1002/oby.21023
127. Ndumele CE, Matsushita K, Lazo M, Bello N, Blumenthal RS, Gerstenblith G, Nambi V, Ballantyne CM, Solomon SD, Selvin E, et al. Obesity and subtypes of incident cardiovascular disease. *J Am Heart Assoc*. 2016;5:e003921. doi: 10.1161/JAHA.116.003921
128. Wilson PW, Bozeman SR, Burton TM, Hoaglin DC, Ben-Joseph R, Pashos CL. Prediction of first events of coronary heart disease and stroke with consideration of adiposity. *Circulation*. 2008;118:124–130. doi: 10.1161/CIRCULATIONAHA.108.772962
129. Mørkedal B, Vatten LJ, Romundstad PR, Laugsand LE, Janszky I. Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals: HUNT (Nord-Trøndelag Health Study), Norway. *J Am Coll Cardiol*. 2014;63:1071–1078. doi: 10.1016/j.jacc.2013.11.035
130. Thomsen M, Nordestgaard BG. Myocardial infarction and ischemic heart disease in overweight and obesity with and without metabolic syndrome. *JAMA Intern Med*. 2014;174:15–22. doi: 10.1001/jamainternmed.2013.10522
131. Lassale C, Tzoulaki I, Moons KGM, Sweeting M, Boer J, Johnson L, Huerta JM, Agnoli C, Freisling H, Weiderpass E, et al. Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis. *Eur Heart J*. 2018;39:397–406. doi: 10.1093/eurheartj/ehx448
132. Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, Danaei G; Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects). Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. *Lancet*. 2014;383:970–983. doi: 10.1016/S0140-6736(13)61836-X
133. Shimabukuro M, Hirata Y, Tabata M, Dagvasumberel M, Sato H, Kurobe H, Fukuda D, Soeki T, Kitagawa T, Takanashi S, et al. Epicardial adipose tissue volume and adipocytokine imbalance are strongly linked to human coronary atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2013;33:1077–1084. doi: 10.1161/ATVBAHA.112.300829
134. Ishii T, Asuwa N, Masuda S, Ishikawa Y. The effects of a myocardial bridge on coronary atherosclerosis and ischaemia. *J Pathol*. 1998;185:4–9. doi: 10.1002/(SICI)1096-9896(199805)185:1<4::AID-PATH50>3.0.CO;2-3
135. Ishikawa Y, Ishii T, Asuwa N, Masuda S. Absence of atherosclerosis evolution in the coronary arterial segment covered by myocardial tissue in cholesterol-fed rabbits. *Virchows Arch*. 1997;430:163–171. doi: 10.1007/BF01008038
136. Schindler TH, Schelbert HR, Quercioli A, Dilsizian V. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. *JACC Cardiovasc Imaging*. 2010;3:623–640. doi: 10.1016/j.jcmg.2010.04.007
137. Taqueti VR, Di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review. *J Am Coll Cardiol*. 2018;72:2625–2641. doi: 10.1016/j.jacc.2018.09.042
138. Lee BK, Lim HS, Fearon WF, Yong AS, Yamada R, Tanaka S, Lee DP, Yeung AC, Tremmel JA. Invasive evaluation of patients with angina in the absence of obstructive coronary artery disease. *Circulation*. 2015;131:1054–1060. doi: 10.1161/CIRCULATIONAHA.114.012636
139. Taqueti VR, Hachamovitch R, Murthy VL, Naya M, Foster CR, Hainer J, Dorbala S, Blankstein R, Di Carli MF. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. *Circulation*. 2015;131:19–27. doi: 10.1161/CIRCULATIONAHA.114.011939
140. Schindler TH, Cardenas J, Prior JO, Facta AD, Kreissl MC, Zhang XL, Sayre J, Dahlbom M, Licinio J, Schelbert HR. Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function. *J Am Coll Cardiol*. 2006;47:1188–1195. doi: 10.1016/j.jacc.2005.10.062
141. Bajaj NS, Osborne MT, Gupta A, Tavakkoli A, Bravo PE, Vita T, Bibbo CF, Hainer J, Dorbala S, Blankstein R, et al. Coronary microvascular dysfunction and cardiovascular risk in obese patients. *J Am Coll Cardiol*. 2018;72:707–717. doi: 10.1016/j.jacc.2018.05.049
142. Quercioli A, Montecucco F, Pataky Z, Thomas A, Ambrosio G, Staub C, Di Marzo V, Ratib O, Mach F, Golay A, et al. Improvement in coronary circulatory function in morbidly obese individuals after gastric bypass-induced weight loss: relation to alterations in endocannabinoids and adipocytokines. *Eur Heart J*. 2013;34:2063–2073. doi: 10.1093/eurheartj/ehs085
143. Nomura A, Zareba W, Moss AJ. Obesity does not influence electrocardiographic parameters in coronary patients. *Am J Cardiol*. 2000;85:106–108, A9. doi: 10.1016/s0002-9149(99)00617-7
144. Adachi H, Hashimoto R, Tsuruta M, Jacobs DR Jr, Crow RS, Imaizumi T. Hyperinsulinemia and the development of ST-T electrocardiographic abnormalities: an 11-year follow-up study. *Diabetes Care*. 1997;20:1688–1692. doi: 10.2337/diacare.20.11.1688
145. Karason K, Lindroos AK, Stenlöf K, Sjöström L. Relief of cardiorespiratory symptoms and increased physical activity after surgically induced weight loss: results from the Swedish Obese Subjects study. *Arch Intern Med*. 2000;160:1797–1802. doi: 10.1001/archinte.160.12.1797
146. Gondoni LA, Titon AM, Nibbio F, Augello G, Caetani G, Liuzzi A. Heart rate behavior during an exercise stress test in obese patients. *Nutr Metab Cardiovasc Dis*. 2009;19:170–176. doi: 10.1016/j.numecd.2008.07.001
147. Lear SA, Brozic A, Myers JN, Ignaszewski A. Exercise stress testing: an overview of current guidelines. *Sports Med*. 1999;27:285–312. doi: 10.2165/00007256-199927050-00002
148. Chrysohoou C, Skoumas J, Georgiopoulos G, Liontou C, Vogiatzi G, Tsioufis K, Lerakis S, Soulis D, Pitsavos C, Tousoulis D. Exercise capacity and haemodynamic response among 12,327 individuals with cardio-metabolic risk factors undergoing treadmill exercise. *Eur J Prev Cardiol*. 2017;24:1627–1636. doi: 10.1177/2047487317726069
149. Bires AM, Lawson D, Wasser TE, Raber-Baer D. Comparison of Bruce treadmill exercise test protocols: is ramped Bruce equal or superior to standard Bruce in producing clinically valid studies for patients presenting for evaluation of cardiac ischemia or arrhythmia with body mass index equal to or greater than 30? *J Nucl Med Technol*. 2013;41:274–278. doi: 10.2967/jnmt.113.124727
150. Korbee RS, Boiten HJ, Ottenhof M, Valkema R, van Domburg RT, Schinkel AF. What is the value of stress (99m)Tc-tetrofosmin myocardial perfusion imaging for the assessment of very long-term outcome in obese patients? *J Nucl Cardiol*. 2013;20:227–233. doi: 10.1007/s12350-012-9657-z
151. Chow BJ, Dorbala S, Di Carli MF, Merhige MF, Williams BA, Veledar E, Min JK, Pencina MJ, Yam Y, Chen L, et al. Prognostic value of PET myocardial perfusion imaging in obese patients. *JACC Cardiovasc Imaging*. 2014;7:278–287. doi: 10.1016/j.jcmg.2013.12.008
152. Supariwala A, Makani H, Kahan J, Pierce M, Bajwa F, Dukkupati SS, Teixeira J, Chaudhry FA. Feasibility and prognostic value of stress echocardiography in obese, morbidly obese, and super obese patients referred for bariatric surgery. *Echocardiography*. 2014;31:879–885. doi: 10.1111/echo.12481
153. Argulian E, Halpern DG, Agarwal V, Agarwal SK, Chaudhry FA. Predictors of ischemia in patients referred for evaluation of exertional dyspnea: a stress echocardiography study. *J Am Soc Echocardiogr*. 2013;26:72–76. doi: 10.1016/j.echo.2012.09.012
154. Hu SJ, Liu SX, Katus HA, Luedde M. The value of contrast dobutamine stress echocardiography on detecting coronary artery disease in overweight and obese patients. *Can J Cardiol*. 2007;23:885–889. doi: 10.1016/s0828-282x(07)70844-9
155. Shah BN, Senior R. Stress echocardiography in patients with morbid obesity. *Echo Res Pract*. 2016;3:R13–R18. doi: 10.1530/ERP-16-0010
156. Lerakis S, Kalogeropoulos AP, El-Chami MF, Georgiopoulos VV, Abraham A, Lynch SA, Lewis AJ, Leach GC, Osier EJ, Veledar E, et al. Transthoracic dobutamine stress echocardiography in patients undergoing bariatric surgery. *Obes Surg*. 2007;17:1475–1481. doi: 10.1007/s11695-008-9425-y
157. Mulvagh SL, DeMaria AN, Feinstein SB, Burns PN, Kaul S, Miller JG, Monaghan M, Porter TR, Shaw LJ, Villanueva FS. Contrast echocardiography: current and future applications. *J Am Soc Echocardiogr*. 2000;13:331–342. doi: 10.1067/mje.2000.105462
158. Medical Advisory Secretariat. Stress echocardiography with contrast for the diagnosis of coronary artery disease: an evidence-based analysis. *Ont Health Technol Assess Ser*. 2010;10:1–59.
159. Madu EC. Transesophageal dobutamine stress echocardiography in the evaluation of myocardial ischemia in morbidly obese subjects. *Chest*. 2000;117:657–661. doi: 10.1378/chest.117.3.657
160. Legault S, Sénéchal M, Bergeron S, Arseneault M, Tessier M, Guimond J, Poirier P. Usefulness of an accelerated transoesophageal stress echocardiography in the preoperative evaluation of high risk severely obese subjects awaiting bariatric surgery. *Cardiovasc Ultrasound*. 2010;8:30. doi: 10.1186/1476-7120-8-30
161. Shah RV, Heydari B, Coelho-Filho O, Abbasi SA, Feng JH, Neilan TG, Francis S, Blankstein R, Steigner M, Jerosch-Herold M, et al. Vasodilator stress perfusion CMR imaging is feasible and prognostic in obese

- patients. *JACC Cardiovasc Imaging*. 2014;7:462–472. doi: 10.1016/j.jcmg.2013.11.011
162. Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM, Lauer MS, Post WS, Raggi P, Redberg RF, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). *Circulation*. 2007;115:402–426. doi: 10.1161/CIRCULATIONAHA.107.181425
 163. Chang Y, Kim BK, Yun KE, Cho J, Zhang Y, Rampal S, Zhao D, Jung HS, Choi Y, Ahn J, et al. Metabolically-healthy obesity and coronary artery calcification. *J Am Coll Cardiol*. 2014;63:2679–2686. doi: 10.1016/j.jacc.2014.03.042
 164. Kronmal RA, McClelland RL, Detrano R, Shea S, Lima JA, Cushman M, Bild DE, Burke GL. Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA). *Circulation*. 2007;115:2722–2730. doi: 10.1161/CIRCULATIONAHA.106.674143
 165. See R, Abdullah SM, McGuire DK, Khera A, Patel MJ, Lindsey JB, Grundy SM, de Lemos JA. The association of differing measures of overweight and obesity with prevalent atherosclerosis: the Dallas Heart Study. *J Am Coll Cardiol*. 2007;50:752–759. doi: 10.1016/j.jacc.2007.04.066
 166. Park J, Lee ES, Lee DY, Kim J, Park SE, Park CY, Lee WY, Oh KW, Park SW, Rhee EJ. Waist circumference as a marker of obesity is more predictive of coronary artery calcification than body mass index in apparently healthy Korean adults: the Kangbuk Samsung Health Study. *Endocrinol Metab (Seoul)*. 2016;31:559–566. doi: 10.3803/EnM.2016.31.4.559
 167. Labounty TM, Gomez MJ, Achenbach S, Al-Mallah M, Berman DS, Budoff MJ, Cademartiri F, Callister TQ, Chang HJ, Cheng V, et al. Body mass index and the prevalence, severity, and risk of coronary artery disease: an international multicentre study of 13 874 patients. *Eur Heart J Cardiovasc Imaging*. 2013;14:456–463. doi: 10.1093/ehjci/jes179
 168. Imai A, Komatsu S, Ohara T, Kamata T, Yoshida J, Miyaji K, Takewa M, Kodama K. Visceral abdominal fat accumulation predicts the progression of noncalcified coronary plaque. *Atherosclerosis*. 2012;222:524–529. doi: 10.1016/j.atherosclerosis.2012.03.018
 169. Husmann L, Leschka S, Boehm T, Desbiolles L, Schepis T, Koepfl P, Gaemperli O, Marincek B, Kaufmann P, Alkadhi H. Influence of body mass index on coronary artery opacification in 64-slice CT angiography [in German]. *Rofo*. 2006;178:1007–1013. doi: 10.1055/s-2006-926871
 170. Hibbert B, Simard T, Wilson KR, Hawken S, Wells GA, Ramirez FD, Le May MR, So DY, Glover CA, Froeschl M, et al. Transradial versus femoral artery approach for coronary angiography and percutaneous coronary intervention in the extremely obese. *JACC Cardiovasc Interv*. 2012;5:819–826. doi: 10.1016/j.jcin.2012.04.009
 171. McNulty PH, Ettinger SM, Field JM, Gilchrist IC, Kozak M, Chambers CE, Gascho JA. Cardiac catheterization in morbidly obese patients. *Catheter Cardiovasc Interv*. 2002;56:174–177. doi: 10.1002/ccd.10186
 172. Wong P, Harding S, Walters D, Hull ML, Jang IK. Vascular complications after hemostatic puncture closure device (Angio-Seal) are not higher in overweight patients. *J Invasive Cardiol*. 2001;13:623–625.
 173. Plourde G, Panchoy SB, Nolan J, Jolly S, Rao SV, Ahmed I, Bangalore S, Patel T, Dahm JB, Bertrand OF. Radiation exposure in relation to the arterial access site used for diagnostic coronary angiography and percutaneous coronary intervention: a systematic review and meta-analysis. *Lancet*. 2015;386:2192–2203. doi: 10.1016/S0140-6736(15)00305-0
 174. Motoyama S, Ito H, Sarai M, Kondo T, Kawai H, Nagahara Y, Harigaya H, Kan S, Anno H, Takahashi H, et al. Plaque characterization by coronary computed tomography angiography and the likelihood of acute coronary events in mid-term follow-up. *J Am Coll Cardiol*. 2015;66:337–346. doi: 10.1016/j.jacc.2015.05.069
 175. Ohashi N, Yamamoto H, Horiguchi J, Kitagawa T, Kunita E, Utsunomiya H, Oka T, Kohno N, Kihara Y. Association between visceral adipose tissue area and coronary plaque morphology assessed by CT angiography. *JACC Cardiovasc Imaging*. 2010;3:908–917. doi: 10.1016/j.jcmg.2010.06.014
 176. Khan SS, Ning H, Wilkins JT, Allen N, Carnethon M, Berry JD, Sweis RN, Lloyd-Jones DM. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. *JAMA Cardiol*. 2018;3:280–287. doi: 10.1001/jamacardio.2018.0022
 177. Lavie CJ, Laddu D, Arena R, Ortega FB, Alpert MA, Kushner RF. Promotion of: healthy weight and obesity prevention: *JACC Health Promotion Series*. *J Am Coll Cardiol*. 2018;72(Pt B):3027–3052. doi: 10.1016/j.jacc.2018.10.024
 178. Elagizi A, Kachur S, Lavie CJ, Carbone S, Pandey A, Ortega FB, Milani RV. An overview and update on obesity and the obesity paradox in cardiovascular diseases. *Prog Cardiovasc Dis*. 2018;61:142–150. doi: 10.1016/j.pcad.2018.07.003
 179. Horwich TB, Fonarow GC, Clark AL. Obesity and the obesity paradox in heart failure. *Prog Cardiovasc Dis*. 2018;61:151–156. doi: 10.1016/j.pcad.2018.05.005
 180. Bassi N, Karagodin I, Wang S, Vassallo P, Priyath A, Massaro E, Stone NJ. Lifestyle modification for metabolic syndrome: a systematic review. *Am J Med*. 2014;127:1242.e1–1242.e10. doi: 10.1016/j.amjmed.2014.06.035
 181. Lien LF, Brown AJ, Ard JD, Loria C, Erlinger TP, Feldstein AC, Lin PH, Champagne CM, King AC, McGuire HL, et al. Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome. *Hypertension*. 2007;50:609–616. doi: 10.1161/HYPERTENSIONAHA.107.089458
 182. Wing R, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, et al; Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *N Engl J Med*. 2013;369:145–154.
 183. Ma C, Avenell A, Bolland M, Hudson J, Stewart F, Robertson C, Sharma P, Fraser C, MacLennan G. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. *BMJ*. 2017;359:j4849. doi: 10.1136/bmj.j4849
 184. Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Thomas RJ, Squires RW, Allison TG. Prognostic importance of weight loss in patients with coronary heart disease regardless of initial body mass index. *Eur J Cardiovasc Prev Rehabil*. 2008;15:336–340. doi: 10.1097/HJR.0b013e3282f48348
 185. Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, Ahlin S, Anveden Å, Bengtsson C, Bergmark G, et al. Bariatric surgery and long-term cardiovascular events. *JAMA*. 2012;307:56–65. doi: 10.1001/jama.2011.1914
 186. Batsis JA, Sarr MG, Collazo-Clavell ML, Thomas RJ, Romero-Corral A, Somers VK, Lopez-Jimenez F. Cardiovascular risk after bariatric surgery for obesity. *Am J Cardiol*. 2008;102:930–937. doi: 10.1016/j.amjcard.2008.05.040
 187. Cornier MA, Després JP, Davis N, Grossniklaus DA, Klein S, Lamarche B, Lopez-Jimenez F, Rao G, St-Onge MP, Towfighi A, et al; on behalf of the American Heart Association Obesity Committee of the Council on Nutrition; Physical Activity and Metabolism; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing, Council on Epidemiology and Prevention; Council on the Kidney in Cardiovascular Disease, and Stroke Council. Assessing adiposity: a scientific statement from the American Heart Association. *Circulation*. 2011;124:1996–2019. doi: 10.1161/CIR.0b013e318233bc6a
 188. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, et al; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med*. 2013;368:1279–1290. doi: 10.1056/NEJMoa1200303
 189. Heffron SP, Parham JS, Pendse J, Alemán JO. Treatment of obesity in mitigating metabolic risk. *Circ Res*. 2020;126:1646–1665. doi: 10.1161/CIRCRESAHA.119.315897
 190. Gregg EW, Jakicic JM, Lewis CE, Regensteiner JG, Pi-Sunyer X, Wing RR, Curtis JM, Yanovski SZ, Evans M, Lang W, et al; Look AHEAD Research Group. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. *Lancet Diabetes Endocrinol*. 2016;4:913–921. doi: 10.1016/S2213-8587(16)30162-0
 191. Marso SP, Daniels GH, Brown-Franden K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375:311–322. doi: 10.1056/NEJMoa1603827
 192. Bohula EA, Wiviott SD, Scirica BM. Lorcaserin safety in overweight or obese patients. *N Engl J Med*. 2019;380:100. doi: 10.1056/NEJMc1813971

193. Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, Perez A, Smith SR. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. *JAMA*. 2016;315:990–1004. doi: 10.1001/jama.2016.1558
194. Fisher DP, Johnson E, Haneuse S, Arterburn D, Coleman KJ, O'Connor PJ, O'Brien R, Bogart A, Theis MK, Anau J, et al. Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity. *JAMA*. 2018;320:1570–1582. doi: 10.1001/jama.2018.14619
195. Payvar S, Kim S, Rao SV, Krone R, Neely M, Paladugu N, Daggubati R. In-hospital outcomes of percutaneous coronary interventions in extremely obese and normal-weight patients: findings from the NCDR (National Cardiovascular Data Registry). *J Am Coll Cardiol*. 2013;62:692–696. doi: 10.1016/j.jacc.2013.05.058
196. Joncas SX, Poirier P, Ardiouze JL, Carrier N, Fayat T, Farand P. Delayed efficient anticoagulation with heparin in patients with a weight of 110 kg and more treated for acute coronary syndrome. *Obesity (Silver Spring)*. 2013;21:1753–1758. doi: 10.1002/oby.20029
197. Buschur ME, Smith D, Share D, Campbell W, Mattchak S, Sharma M, Gurm HS. The burgeoning epidemic of morbid obesity in patients undergoing percutaneous coronary intervention: insight from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. *J Am Coll Cardiol*. 2013;62:685–691. doi: 10.1016/j.jacc.2013.06.004
198. Holroyd EW, Sirker A, Kwok CS, Kontopantelis E, Ludman PF, De Belder MA, Butler R, Cotton J, Zaman A, Mamas MA; British Cardiovascular Intervention Society and National Institute of Cardiovascular Outcomes Research. The relationship of body mass index to percutaneous coronary intervention outcomes: does the obesity paradox exist in contemporary percutaneous coronary intervention cohorts? Insights from the British Cardiovascular Intervention Society Registry. *JACC Cardiovasc Interv*. 2017;10:1283–1292. doi: 10.1016/j.jcin.2017.03.013
199. Terada T, Forhan M, Norris CM, Qiu WY, Padwal R, Sharma AM, Nagendran J, Johnson JA. Differences in short- and long-term mortality associated with BMI following coronary revascularization. *J Am Heart Assoc*. 2017;6:e005335. doi: 10.1161/JAHA.116.005335
200. Lancefield T, Clark DJ, Andrianopoulos N, Brennan AL, Reid CM, Johns J, Freeman M, Charter K, Duffy SJ, Ajani AE, et al; MIG (Melbourne Interventional Group) Registry. Is there an obesity paradox after percutaneous coronary intervention in the contemporary era? An analysis from a multicenter Australian registry. *JACC Cardiovasc Interv*. 2010;3:660–668. doi: 10.1016/j.jcin.2010.03.018
201. Mehta L, Devlin W, McCullough PA, O'Neill WW, Skelding KA, Stone GW, Boura JA, Grines CL. Impact of body mass index on outcomes after percutaneous coronary intervention in patients with acute myocardial infarction. *Am J Cardiol*. 2007;99:906–910. doi: 10.1016/j.amjcard.2006.11.038
202. Park DW, Kim YH, Yun SC, Ahn JM, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Park SW, et al. Association of body mass index with major cardiovascular events and with mortality after percutaneous coronary intervention. *Circ Cardiovasc Interv*. 2013;6:146–153. doi: 10.1161/CIRCINTERVENTIONS.112.000062
203. Ma WQ, Sun XJ, Wang Y, Han XQ, Zhu Y, Liu NF. Does body mass index truly affect mortality and cardiovascular outcomes in patients after coronary revascularization with percutaneous coronary intervention or coronary artery bypass graft? A systematic review and network meta-analysis. *Obes Rev*. 2018;19:1236–1247. doi: 10.1111/obr.12713
204. Li YH, Lin GM, Lin CL, Wang JH, Han CL. Relation of body mass index to mortality among patients with percutaneous coronary intervention longer than 5 years follow-up: a meta-analysis. *Int J Cardiol*. 2013;168:4315–4318. doi: 10.1016/j.ijcard.2013.04.174
205. Unek IT, Bayraktar F, Solmaz D, Ellidokuz H, Sisman AR, Yuksel F, Yesil S. The levels of soluble CD40 ligand and C-reactive protein in normal weight, overweight and obese people. *Clin Med Res*. 2010;8:89–95. doi: 10.3121/cm.2010.889
206. Beavers CJ, Heron P, Smyth SS, Bain JA, Macaulay TE. Obesity and antiplatelets: does one size fit all? *Thromb Res*. 2015;136:712–716. doi: 10.1016/j.thromres.2015.07.015
207. Farb MG, Bigornia S, Mott M, Tanriverdi K, Morin KM, Freedman JE, Joseph L, Hess DT, Apovian CM, Vita JA, et al. Reduced adipose tissue inflammation represents an intermediate cardiometabolic phenotype in obesity. *J Am Coll Cardiol*. 2011;58:232–237. doi: 10.1016/j.jacc.2011.01.051
208. Neergaard-Petersen S, Hvas AM, Kristensen SD, Grove EL. Platelets and antiplatelet therapy in patients with coronary artery disease and diabetes. *Semin Thromb Hemost*. 2016;42:234–241. doi: 10.1055/s-0036-1571308
209. Norgard NB. Obesity and altered aspirin pharmacology. *Clin Pharmacokinet*. 2018;57:663–672. doi: 10.1007/s40262-017-0611-8
210. Bordeaux BC, Qayyum R, Yanek LR, Vaidya D, Becker LC, Faraday N, Becker DM. Effect of obesity on platelet reactivity and response to low-dose aspirin. *Prev Cardiol*. 2010;13:56–62. doi: 10.1111/j.1751-7141.2009.00058.x
211. Tamminen M, Lassila R, Westerbacka J, Vehkavaara S, Yki-Järvinen H. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. *Int J Obes Relat Metab Disord*. 2003;27:907–911. doi: 10.1038/sj.ijo.0802312
212. Bhatt DL, Groussier T, Dong JF, Logan D, Jeske W, Angiolillo DJ, Frelinger AL 3rd, Lei L, Liang J, Moore JE, et al. Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus. *J Am Coll Cardiol*. 2017;69:603–612. doi: 10.1016/j.jacc.2016.11.050
213. Stohlawetz P, Folman CC, von dem Borne AE, Pernerstorfer T, Eichler HG, Panzer S, Jilma B. Effects of endotoxemia on thrombopoiesis in men. *Thromb Haemost*. 1999;81:613–617.
214. Guthikonda S, Alviar CL, Vaduganathan M, Arkan M, Tellez A, DeLao T, Granada JF, Dong JF, Kleiman NS, Lev EI. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. *J Am Coll Cardiol*. 2008;52:743–749. doi: 10.1016/j.jacc.2008.05.031
215. Pankert M, Quilici J, Loundou AD, Verdier V, Lambert M, Deharo P, Bonnet G, Gaborit B, Morange PE, Valéro R, et al. Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting. *Am J Cardiol*. 2014;113:54–59. doi: 10.1016/j.amjcard.2013.09.011
216. Deharo P, Pankert M, Bonnet G, Quilici J, Bassez C, Morange P, Alessi MC, Bonnet JL, Cuisset T. Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel. *Int J Cardiol*. 2014;176:1200–1202. doi: 10.1016/j.ijcard.2014.07.228
217. Prabhakar G, Haan CK, Peterson ED, Coombs LP, Cruzzavala JL, Murray GF. The risks of moderate and extreme obesity for coronary artery bypass grafting outcomes: a study from the Society of Thoracic Surgeons database. *Ann Thorac Surg*. 2002;74:1125–1130. doi: 10.1016/s0003-4975(02)03899-7
218. Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Obesity is not a risk factor for significant adverse outcomes after cardiac surgery. *Circulation*. 1996;94(suppl):II87–II92.
219. Birkmeyer NJ, Charlesworth DC, Hernandez F, Leavitt BJ, Marrin CA, Morton JR, Olmstead EM, O'Connor GT. Obesity and risk of adverse outcomes associated with coronary artery bypass surgery: Northern New England Cardiovascular Disease Study Group. *Circulation*. 1998;97:1689–1694. doi: 10.1161/01.cir.97.17.1689
220. Oreopoulos A, Padwal R, Norris CM, Mullen JC, Pretorius V, Kalantar-Zadeh K. Effect of obesity on short- and long-term mortality postcoronary revascularization: a meta-analysis. *Obesity (Silver Spring)*. 2008;16:442–450. doi: 10.1038/oby.2007.36
221. Prapas SN, Panagiotopoulos IA, Salama Ayyad MA, Protogeris DA, Linardakis IN, Kotsis VN, Katinioti AA, Michalopoulos AS. Impact of obesity on outcome of patients undergoing off-pump coronary artery bypass grafting using aorta no-touch technique. *Interact Cardiovasc Thorac Surg*. 2010;11:234–237. doi: 10.1510/icvts.2010.234443
222. Wagner BD, Grunwald GK, Rumsfeld JS, Hill JO, Ho PM, Wyatt HR, Shroyer AL. Relationship of body mass index with outcomes after coronary artery bypass graft surgery. *Ann Thorac Surg*. 2007;84:10–16. doi: 10.1016/j.athoracsur.2007.03.017
223. Benedetto U, Danese C, Codispoti M. Obesity paradox in coronary artery bypass grafting: myth or reality? *J Thorac Cardiovasc Surg*. 2014;147:1517–1523. doi: 10.1016/j.jtcvs.2013.05.028
224. Virani SS, Nambi V, Lee VV, Elayda MA, Pan W, Petersen LA, Wilson JM, Willerson JT, Ballantyne CM. Obesity an independent predictor of in-hospital postoperative renal insufficiency among patients undergoing cardiac surgery? *Tex Heart J J*. 2009;36:540–545.
225. Nolan HR, Davenport DL, Ramaiah C. BMI is an independent preoperative predictor of intraoperative transfusion and postoperative chest-tube output. *Int J Angiol*. 2013;22:31–36. doi: 10.1055/s-0033-1333865
226. Totaro P. Obesity and coronary surgery: new concepts for an old problem. *Expert Rev Cardiovasc Ther*. 2008;6:897–903. doi: 10.1586/14779072.6.6.897

227. Hernandez AV, Kaw R, Pasupuleti V, Bina P, Ioannidis JP, Bueno H, Boersma E, Gillinov M; Cardiovascular Meta-Analyses Research Group. Association between obesity and postoperative atrial fibrillation in patients undergoing cardiac operations: a systematic review and meta-analysis. *Ann Thorac Surg*. 2013;96:1104–1116. doi: 10.1016/j.athoracsur.2013.04.029
228. Chassé M, Mathieu P, Voisine P, Després JP, Pibarot P, Baillot R, Lellouche F, Poirier P. The underestimated belly factor: waist circumference is linked to significant morbidity following isolated coronary artery bypass grafting. *Can J Cardiol*. 2016;32:327–335. doi: 10.1016/j.cjca.2015.06.031
229. Ruka E, Dagenais F, Mohammadi S, Chauvette V, Poirier P, Voisine P. Bilateral mammary artery grafting increases postoperative mediastinitis without survival benefit in obese patients. *Eur J Cardiothorac Surg*. 2016;50:1188–1195. doi: 10.1093/ejcts/ezw164
230. Parisian Mediastinitis Study Group. Risk factors for deep sternal wound infection after sternotomy: a prospective, multicenter study. *J Thorac Cardiovasc Surg*. 1996;111:1200–1207.
231. Alpert MA, Lavie CJ, Agrawal H, Aggarwal KB, Kumar SA. Obesity and heart failure: epidemiology, pathophysiology, clinical manifestations, and management. *Transl Res*. 2014;164:345–356. doi: 10.1016/j.trsl.2014.04.010
232. Csige I, Ujvárosy D, Szabó Z, Lőrincz I, Paragh G, Harangi M, Somodi S. The impact of obesity on the cardiovascular system. *J Diabetes Res*. 2018;2018:3407306. doi: 10.1155/2018/3407306
233. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. *Circulation*. 2017;136:6–19. doi: 10.1161/CIRCULATIONAHA.116.026807
234. Kitzman DW, Lam CSP. Obese heart failure with preserved ejection fraction phenotype: from pariah to central player. *Circulation*. 2017;136:20–23. doi: 10.1161/CIRCULATIONAHA.117.028365
235. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the risk of heart failure. *N Engl J Med*. 2002;347:305–313. doi: 10.1056/NEJMoa020245
236. Hu G, Jousilahti P, Antikainen R, Katzmarzyk PT, Tuomilehto J. Joint effects of physical activity, body mass index, waist circumference, and waist-to-hip ratio on the risk of heart failure. *Circulation*. 2010;121:237–244. doi: 10.1161/CIRCULATIONAHA.109.887893
237. Bozkurt B, Aguilar D, Deswal A, Dunbar SB, Francis GS, Horwich T, Jessup M, Kosiborod M, Pritchett AM, Ramasubbu K, et al; on behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; Council on Hypertension; and Council on Quality and Outcomes Research. Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association. *Circulation*. 2016;134:e535–e578. doi: 10.1161/CIR.0000000000000450
238. Loehr LR, Rosamond WD, Poole C, McNeill AM, Chang PP, Folsom AR, Chambless LE, Heiss G. Association of multiple anthropometrics of overweight and obesity with incident heart failure: the Atherosclerosis Risk in Communities Study. *Circ Heart Fail*. 2009;2:18–24. doi: 10.1161/CIRCHEARTFAILURE.108.813782
239. Levitan EB, Yang AZ, Wolk A, Mittleman MA. Adiposity and incidence of heart failure hospitalization and mortality: a population-based prospective study. *Circ Heart Fail*. 2009;2:202–208. doi: 10.1161/CIRCHEARTFAILURE.108.794099
240. Rodriguez Flores M, Aguilar Salinas C, Piché ME, Auclair A, Poirier P. Effect of bariatric surgery on heart failure. *Expert Rev Cardiovasc Ther*. 2017;15:567–579. doi: 10.1080/14779072.2017.1352471
241. Neeland IJ, Gupta S, Ayers CR, Turer AT, Rame JE, Das SR, Berry JD, Khara A, McGuire DK, Vega GL, et al. Relation of regional fat distribution to left ventricular structure and function. *Circ Cardiovasc Imaging*. 2013;6:800–807. doi: 10.1161/CIRCIMAGING.113.000532
242. Murase T, Hattori T, Ohtake M, Abe M, Amakusa Y, Takatsu M, Murohara T, Nagata K. Cardiac remodeling and diastolic dysfunction in DahlS.Z-Lepr(fa)/Lepr(fa) rats: a new animal model of metabolic syndrome. *Hypertens Res*. 2012;35:186–193. doi: 10.1038/hr.2011.157
243. Pandey A, Patel KV, Vaduganathan M, Sarma S, Haykowsky MJ, Berry JD, Lavie CJ. Physical activity, fitness, and obesity in heart failure with preserved ejection fraction. *JACC Heart Fail*. 2018;6:975–982. doi: 10.1016/j.jchf.2018.09.006
244. Pandey A, LaMonte M, Klein L, Ayers C, Psaty BM, Eaton CB, Allen NB, de Lemos JA, Carnethon M, Greenland P, et al. Relationship between physical activity, body mass index, and risk of heart failure. *J Am Coll Cardiol*. 2017;69:1129–1142. doi: 10.1016/j.jacc.2016.11.081
245. Pandey A, Cornwell WK 3rd, Willis B, Neeland IJ, Gao A, Leonard D, DeFina L, Berry JD. Body mass index and cardiorespiratory fitness in mid-life and risk of heart failure hospitalization in older age: findings from the Cooper Center Longitudinal Study. *JACC Heart Fail*. 2017;5:367–374. doi: 10.1016/j.jchf.2016.12.021
246. Clark AL, Chyu J, Horwich TB. The obesity paradox in men versus women with systolic heart failure. *Am J Cardiol*. 2012;110:77–82. doi: 10.1016/j.amjcard.2012.02.050
247. Clark AL, Fonarow GC, Horwich TB. Waist circumference, body mass index, and survival in systolic heart failure: the obesity paradox revisited. *J Card Fail*. 2011;17:374–380. doi: 10.1016/j.cardfail.2011.01.009
248. Tsujimoto T, Kajio H. Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF. *J Am Coll Cardiol*. 2017;70:2739–2749. doi: 10.1016/j.jacc.2017.09.1111
249. Lavie CJ, Milani RV, Ventura HO. Adipose composition and heart failure prognosis: paradox or not? *J Am Coll Cardiol*. 2017;70:2750–2751. doi: 10.1016/j.jacc.2017.10.017
250. Futter JE, Cleland JG, Clark AL. Body mass indices and outcome in patients with chronic heart failure. *Eur J Heart Fail*. 2011;13:207–213. doi: 10.1093/eurjhf/hfq218
251. Doesch C, Suselbeck T, Leweling H, Fluechter S, Haghi D, Schoenberg SO, Borggreffe M, Papavassiliu T. Bioimpedance analysis parameters and epicardial adipose tissue assessed by cardiac magnetic resonance imaging in patients with heart failure. *Obesity (Silver Spring)*. 2010;18:2326–2332. doi: 10.1038/oby.2010.65
252. Martin J, Bergeron S, Pibarot P, Bastien M, Biertho L, Lesclieur O, Bertrand F, Simard S, Poirier P. Impact of bariatric surgery on N-terminal fragment of the prohormone brain natriuretic peptide and left ventricular diastolic function. *Can J Cardiol*. 2013;29:969–975. doi: 10.1016/j.cjca.2012.11.010
253. Emami A, Saitoh M, Valentova M, Sandek A, Evertz R, Ebner N, Loncar G, Springer J, Doehner W, Lainscak M, et al. Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-Morbidities Aggravating Heart Failure (SICA-HF). *Eur J Heart Fail*. 2018;20:1580–1587. doi: 10.1002/ehf.1304
254. Ventura HO, Carbone S, Lavie CJ. Muscling up to improve heart failure prognosis. *Eur J Heart Fail*. 2018;20:1588–1590. doi: 10.1002/ehf.1314
255. Carbone S, Billingsley HE, Rodriguez-Miguel P, Kirkman DL, Garten R, Franco RL, Lee DC, Lavie CJ. Lean mass abnormalities in heart failure: the role of sarcopenia, sarcopenic obesity, and cachexia. *Curr Probl Cardiol*. 2020;45:100417. doi: 10.1016/j.cpcardiol.2019.03.006
256. Pathak RK, Mahajan R, Lau DH, Sanders P. The implications of obesity for cardiac arrhythmia mechanisms and management. *Can J Cardiol*. 2015;31:203–210. doi: 10.1016/j.cjca.2014.10.027
257. Plourde B, Sarrazin JF, Nault I, Poirier P. Sudden cardiac death and obesity. *Expert Rev Cardiovasc Ther*. 2014;12:1099–1110. doi: 10.1586/14779072.2014.952283
258. Chiuev SE, Sun Q, Sandhu RK, Tedrow U, Cook NR, Manson JE, Albert CM. Adiposity throughout adulthood and risk of sudden cardiac death in women. *JACC Clin Electrophysiol*. 2015;1:520–528. doi: 10.1016/j.jacep.2015.07.011
259. Adabag S, Huxley RR, Lopez FL, Chen LY, Sotoodehnia N, Siscovick D, Deo R, Konety S, Alonso A, Folsom AR. Obesity related risk of sudden cardiac death in the Atherosclerosis Risk in Communities study. *Heart*. 2015;101:215–221. doi: 10.1136/heartjnl-2014-306238
260. Aune D, Schlesinger S, Norat T, Riboli E. Body mass index, abdominal fatness, and the risk of sudden cardiac death: a systematic review and dose-response meta-analysis of prospective studies. *Eur J Epidemiol*. 2018;33:711–722. doi: 10.1007/s10654-017-0353-9
261. Hookana E, Juntila MJ, Puurunen VP, Tikkanen JT, Kaikkonen KS, Kortelainen ML, Myerburg RJ, Huikuri HV. Causes of nonischemic sudden cardiac death in the current era. *Heart Rhythm*. 2011;8:1570–1575. doi: 10.1016/j.hrthm.2011.06.031
262. Empana JP, Ducimetiere P, Charles MA, Jouven X. Sagittal abdominal diameter and risk of sudden death in asymptomatic middle-aged men: the Paris Prospective Study I. *Circulation*. 2004;110:2781–2785. doi: 10.1161/01.CIR.0000146395.64065.BA
263. Messerli FH, Nunez BD, Ventura HO, Snyder DW. Overweight and sudden death: increased ventricular ectopy in cardiopathy of obesity. *Arch Intern Med*. 1987;147:1725–1728. doi: 10.1001/archinte.147.10.1725

264. Fraley MA, Birchem JA, Senkottaiyan N, Alpert MA. Obesity and the electrocardiogram. *Obes Rev*. 2005;6:275–281. doi: 10.1111/j.1467-789X.2005.00199.x
265. Pietrasik G, Goldenberg I, McNitt S, Moss AJ, Zareba W. Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients. *J Cardiovasc Electrophysiol*. 2007;18:181–184. doi: 10.1111/j.1540-8167.2006.00680.x
266. Sabbag A, Goldenberg I, Moss AJ, McNitt S, Glikson M, Biton Y, Jackson L, Polonsky B, Zareba W, Kutyla V. Predictors and risk of ventricular tachyarrhythmias or death in Black and White cardiac patients: a MADIT-CRT Trial substudy. *JACC Clin Electrophysiol*. 2016;2:448–455. doi: 10.1016/j.jacep.2016.03.003
267. Lalani AP, Kanna B, John J, Ferrick KJ, Huber MS, Shapiro LE. Abnormal signal-averaged electrocardiogram (SAECG) in obesity. *Obes Res*. 2000;8:20–28. doi: 10.1038/oby.2000.4
268. Kasper EK, Hruban RH, Baughman KL. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. *Am J Cardiol*. 1992;70:921–924. doi: 10.1016/0002-9149(92)90739-1
269. Duflo J, Virmani R, Rabin I, Burke A, Farb A, Smialek J. Sudden death as a result of heart disease in morbid obesity. *Am Heart J*. 1995;130:306–313. doi: 10.1016/0002-8703(95)90445-x
270. Russo C, Jin Z, Homma S, Rundek T, Elkind MS, Sacco RL, Di Tullio MR. Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort. *J Am Coll Cardiol*. 2011;57:1368–1374. doi: 10.1016/j.jacc.2010.10.042
271. Konno T, Hayashi K, Fujino N, Oka R, Nomura A, Nagata Y, Hodatsu A, Sakata K, Furusho H, Takamura M, et al. Electrocardiographic QRS fragmentation as a marker for myocardial fibrosis in hypertrophic cardiomyopathy. *J Cardiovasc Electrophysiol*. 2015;26:1081–1087. doi: 10.1111/jce.12742
272. Narayanan K, Zhang L, Kim C, Uy-Evanado A, Teodorescu C, Reinier K, Zheng ZJ, Gunson K, Jui J, Chugh SS. QRS fragmentation and sudden cardiac death in the obese and overweight. *J Am Heart Assoc*. 2015;4:e001654. doi: 10.1161/JAHA.114.001654
273. Brenyo A, Pietrasik G, Barsheshet A, Huang DT, Polonsky B, McNitt S, Moss AJ, Zareba W. QRS fragmentation and the risk of sudden cardiac death in MADIT II. *J Cardiovasc Electrophysiol*. 2012;23:1343–1348. doi: 10.1111/j.1540-8167.2012.02390.x
274. Gulati A, Jabbar S, Ismail TF, Guha K, Khwaja J, Raza S, Morarji K, Brown TD, Ismail NA, Dweck MR, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. *JAMA*. 2013;309:896–908. doi: 10.1001/jama.2013.1363
275. Littlejohns B, Pasdois P, Duggan S, Bond AR, Heesom K, Jackson CL, Angelini GD, Halestrap AP, Suleiman MS. Hearts from mice fed a non-obesogenic high-fat diet exhibit changes in their oxidative state, calcium and mitochondria in parallel with increased susceptibility to reperfusion injury. *PLoS One*. 2014;9:e100579. doi: 10.1371/journal.pone.0100579
276. Zarzoso M, Mironov S, Guerrero-Serna G, Willis BC, Pandit SV. Ventricular remodeling in rabbits with sustained high-fat diet. *Acta Physiol (Oxf)*. 2014;211:36–47. doi: 10.1111/apha.12185
277. Wu CK, Tsai HY, Su MY, Wu YF, Hwang JJ, Tseng WY, Lin JL, Lin LY. Pericardial fat is associated with ventricular tachyarrhythmia and mortality in patients with systolic heart failure. *Atherosclerosis*. 2015;241:607–614. doi: 10.1016/j.atherosclerosis.2015.05.025
278. Fuller B, Garland J, Anne S, Beh R, McNeven D, Tse R. Increased epicardial fat thickness in sudden death from stable coronary artery atherosclerosis. *Am J Forensic Med Pathol*. 2017;38:162–166. doi: 10.1097/PAF.0000000000000310
279. Chi PC, Chang SC, Yun CH, Kuo JY, Hung CL, Hou CJ, Liu CY, Yang FS, Wu TH, Bezerra HG, et al. The associations between various ectopic visceral adiposity and body surface electrocardiographic alterations: potential differences between local and remote systemic effects. *PLoS One*. 2016;11:e0158300. doi: 10.1371/journal.pone.0158300
280. Cheng VY, Dey D, Tamarappoo B, Nakazato R, Gansar H, Miranda-Peats R, Ramesh A, Wong ND, Shaw LJ, Slomka PJ, et al. Pericardial fat burden on ECG-gated noncontrast CT in asymptomatic patients who subsequently experience adverse cardiovascular events. *JACC Cardiovasc Imaging*. 2010;3:352–360. doi: 10.1016/j.jcmg.2009.12.013
281. Al-Mosawi AA, Nafakhi H, Hassan MB, Alareedh M, Al-Nafakh HA. ECG markers of arrhythmic risk relationships with pericardial fat volume and BMI in patients with coronary atherosclerosis. *J Electrocardiol*. 2018;51:569–572. doi: 10.1016/j.jelectrocard.2018.03.008
282. Poulipoulos J, Chik WW, Kanthan A, Sivagangabalan G, Barry MA, Fahmy PN, Midekin C, Lu J, Kizana E, Thomas SP, et al. Intramyocardial adiposity after myocardial infarction: new implications of a substrate for ventricular tachycardia. *Circulation*. 2013;128:2296–2308. doi: 10.1161/CIRCULATIONAHA.113.002238
283. Fumagalli S, Boni N, Padeletti M, Gori F, Boncinelli L, Valoti P, Baldasseroni S, Di Bari M, Masotti G, Padeletti L, et al. Determinants of thoracic electrical impedance in external electrical cardioversion of atrial fibrillation. *Am J Cardiol*. 2006;98:82–87. doi: 10.1016/j.amjcard.2006.01.065
284. Jain R, Nallamothu BK, Chan PS, for the American Heart Association National Registry of Cardiopulmonary Resuscitation (NRCPR) Investigators. Body mass index and survival after in-hospital cardiac arrest. *Circ Cardiovasc Qual Outcomes*. 2010;3:490–497. doi: 10.1161/CIRCOUTCOMES.109.912501
285. Shahreyar M, Dang G, Waqas Bashir M, Kumar G, Hussain J, Ahmad S, Pandey B, Thakur A, Bhandari S, Thandra K, et al. Outcomes of in-hospital cardiopulmonary resuscitation in morbidly obese patients. *JACC Clin Electrophysiol*. 2017;3:174–183. doi: 10.1016/j.jacep.2016.08.011
286. Wong CX, Brooks AG, Lau DH, Leong DP, Sun MT, Sullivan T, Roberts-Thomson KC, Sanders P. Factors associated with the epidemic of hospitalizations due to atrial fibrillation. *Am J Cardiol*. 2012;110:1496–1499. doi: 10.1016/j.amjcard.2012.07.011
287. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclellose R, Konety S, Alonso A. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. *Circulation*. 2011;123:1501–1508. doi: 10.1161/CIRCULATIONAHA.110.009035
288. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA, Magnani JW, Ellinor PT, et al. 50 Year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. *Lancet*. 2015;386:154–162. doi: 10.1016/S0140-6736(14)61774-8
289. Rosengren A, Hauptman PJ, Lappas G, Olsson L, Wilhelmsen L, Swedberg K. Big men and atrial fibrillation: effects of body size and weight gain on risk of atrial fibrillation in men. *Eur Heart J*. 2009;30:1113–1120. doi: 10.1093/eurheartj/ehp076
290. Tedrow UB, Conen D, Ridker PM, Cook NR, Koplan BA, Manson JE, Buring JE, Albert CM. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation: the WHS (Women's Health Study). *J Am Coll Cardiol*. 2010;55:2319–2327. doi: 10.1016/j.jacc.2010.02.029
291. Wong CX, Sullivan T, Sun MT, Mahajan R, Pathak RK, Middeldorp M, Twomey D, Ganesan AN, Rangnekar G, Roberts-Thomson KC, et al. Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis of 626,603 individuals in 51 studies. *JACC Clin Electrophysiol*. 2015;1:139–152. doi: 10.1016/j.jacep.2015.04.004
292. Tsang TS, Barnes ME, Miyasaka Y, Cha SS, Bailey KR, Verzosa GC, Seward JB, Gersh BJ. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. *Eur Heart J*. 2008;29:2227–2233. doi: 10.1093/eurheartj/ehn324
293. Abed HS, Samuel CS, Lau DH, Kelly DJ, Royce SG, Alasadat M, Mahajan R, Kuklik P, Zhang Y, Brooks AG, et al. Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. *Heart Rhythm*. 2013;10:90–100. doi: 10.1016/j.hrthm.2012.08.043
294. Mahajan R, Lau DH, Brooks AG, Shipp NJ, Manavis J, Wood JP, Finnie JW, Samuel CS, Royce SG, Twomey DJ, et al. Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity. *J Am Coll Cardiol*. 2015;66:1–11. doi: 10.1016/j.jacc.2015.04.058
295. Munger TM, Dong YX, Masaki M, Oh JK, Mankad SV, Borlaug BA, Asirvatham SJ, Shen WK, Lee HC, Bielinski SJ, et al. Electrophysiological and hemodynamic characteristics associated with obesity in patients with atrial fibrillation. *J Am Coll Cardiol*. 2012;60:851–860. doi: 10.1016/j.jacc.2012.03.042
296. Mahajan R, Nelson A, Pathak RK, Middeldorp ME, Wong CX, Twomey DJ, Carbone A, Teo K, Agbaedeng T, Linz D, et al. Electroanatomical remodeling of the atria in obesity: impact of adjacent epicardial fat. *JACC Clin Electrophysiol*. 2018;4:1529–1540. doi: 10.1016/j.jacep.2018.08.014
297. Al Chekatie MO, Welles CC, Metoyer R, Ibrahim A, Shapira AR, Cytron J, Santucci P, Wilber DJ, Akar JG. Pericardial fat is independently associated with human atrial fibrillation. *J Am Coll Cardiol*. 2010;56:784–788. doi: 10.1016/j.jacc.2010.03.071
298. Wong CX, Abed HS, Molaee P, Nelson AJ, Brooks AG, Sharma G, Leong DP, Lau DH, Middeldorp ME, Roberts-Thomson KC, et al. Pericardial fat is associated with atrial fibrillation severity and ablation outcome. *J Am Coll Cardiol*. 2011;57:1745–1751. doi: 10.1016/j.jacc.2010.11.045

299. Wong CX, Sun MT, Odotayo A, Emdin CA, Mahajan R, Lau DH, Pathak RK, Wong DT, Selvanayagam JB, Sanders P, et al. Associations of epicardial, abdominal, and overall adiposity with atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2016;9:e004378. doi: 10.1161/CIRCEP.116.004378
300. Hatem SN, Sanders P. Epicardial adipose tissue and atrial fibrillation. *Cardiovasc Res*. 2014;102:205–213. doi: 10.1093/cvr/cvu045
301. Lavie CJ, Pandey A, Lau DH, Alpert MA, Sanders P. Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise. *J Am Coll Cardiol*. 2017;70:2022–2035. doi: 10.1016/j.jacc.2017.09.002
302. Lavie CJ, Mehra MR, Ventura HO. Body composition and advanced heart failure therapy: weighing the options and outcomes. *JACC Heart Fail*. 2016;4:769–771. doi: 10.1016/j.jchf.2016.07.007
303. Lavie CJ, Cahalin LP, Chase P, Myers J, Bensimhon D, Peberdy MA, Ashley E, West E, Forman DE, Guazzi M, et al. Impact of cardiorespiratory fitness on the obesity paradox in patients with heart failure. *Mayo Clin Proc*. 2013;88:251–258. doi: 10.1016/j.mayocp.2012.11.020
304. McAuley PA, Keteyian SJ, Brawner CA, Dardari ZA, Al Rifai M, Ehrman JK, Al-Mallah MH, Whelton SP, Blaha MJ. Exercise capacity and the obesity paradox in heart failure: the FIT (Henry Ford Exercise Testing) Project. *Mayo Clin Proc*. 2018;93:701–708. doi: 10.1016/j.mayocp.2018.01.026
305. Pandey A, Patel KV, Lavie CJ. Obesity, central adiposity, and fitness: understanding the obesity paradox in the context of other cardiometabolic parameters. *Mayo Clin Proc*. 2018;93:676–678. doi: 10.1016/j.mayocp.2018.04.015
306. Flynn KE, Piña IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, Fine LJ, Howlett JG, Keteyian SJ, Kitzman DW, et al; HF-ACTION Investigators. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. *JAMA*. 2009;301:1451–1459. doi: 10.1001/jama.2009.457
307. Beck-da-Silva L, Higginson L, Fraser M, Williams K, Haddad H. Effect of orlistat in obese patients with heart failure: a pilot study. *Congest Heart Fail*. 2005;11:118–123. doi: 10.1111/j.1527-5299.2005.03827.x
308. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, et al; NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. *JAMA*. 2016;316:500–508. doi: 10.1001/jama.2016.10260
309. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, Nilsson B, Møller JE, Hjort J, Rasmussen J, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE): a multi-centre, double-blind, randomised, placebo-controlled trial. *Eur J Heart Fail*. 2017;19:69–77. doi: 10.1002/ejhf.657
310. Ghosh RK, Ghosh GC, Gupta M, Bandyopadhyay D, Akhtar T, Deedwania P, Lavie CJ, Fonarow GC, Aneja A. Sodium glucose co-transporter 2 inhibitors and heart failure. *Am J Cardiol*. 2019;124:1790–1796. doi: 10.1016/j.amjcard.2019.08.038
311. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohávek J, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med*. 2019;381:1995–2008. doi: 10.1056/NEJMoa1911303
312. Koshino Y, Villarraga HR, Somers VK, Miranda WR, Garza CA, Hsiao JF, Yu Y, Saleh HK, Lopez-Jimenez F. Changes in myocardial mechanics in patients with obesity following major weight loss after bariatric surgery. *Obesity (Silver Spring)*. 2013;21:1111–1118. doi: 10.1002/oby.20168
313. Shimada YJ, Tsugawa Y, Brown DFM, Hasegawa K. Bariatric surgery and emergency department visits and hospitalizations for heart failure exacerbation: population-based, self-controlled series. *J Am Coll Cardiol*. 2016;67:895–903. doi: 10.1016/j.jacc.2015.12.016
314. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013;128:e240–e327. doi: 10.1161/CIR.0b013e31829e8776
315. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, Twomey D, Elliott AD, Kalman JM, Abhayaratna WP, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). *J Am Coll Cardiol*. 2015;65:2159–2169. doi: 10.1016/j.jacc.2015.03.002
316. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, Lorimer MF, Lau DH, Antic NA, Brooks AG, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. *JAMA*. 2013;310:2050–2060. doi: 10.1001/jama.2013.280521
317. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, Alasady M, Hanley L, Antic NA, McEvoy RD, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. *J Am Coll Cardiol*. 2014;64:2222–2231. doi: 10.1016/j.jacc.2014.09.028
318. Middeldorp ME, Pathak RK, Meredith M, Mehta AB, Elliott AD, Mahajan R, Twomey D, Gallagher C, Hendriks JML, Linz D, et al. PREVENTion and regReSSive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. *Europace*. 2018;20:1929–1935. doi: 10.1093/europace/euy117
319. Lau DH, Nattel S, Kalman JM, Sanders P. Modifiable risk factors and atrial fibrillation. *Circulation*. 2017;136:583–596. doi: 10.1161/CIRCULATIONAHA.116.023163